Analysis method, information processing device, and report providing method

The analysis method simplifies the identification of CDx-relevant mutations and drug effectiveness in gene panel tests by using a computer to generate clear reports, addressing the challenge of expert-intensive mutation identification in gene panel results.

JP7577822B2Active Publication Date: 2024-11-05SYSMEX CORP
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2023205338
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-12-05
Publication Date
2024-11-05
Estimated Expiration
2038-06-29

Smart Images

  • Figure 0007577822000001
    Figure 0007577822000001
  • Figure 0007577822000002
    Figure 0007577822000002
  • Figure 0007577822000003
    Figure 0007577822000003
Patent Text Reader

Abstract

To provide an analysis method for a nucleic acid sequence of a sample capable of easily discriminating gene mutation applicable to CDx from a result of a gene panel inspection, an information processing device for analyzing the nucleic acid sequence of the sample, and a report provision method for providing a report including an analysis result of the nucleic acid sequence.SOLUTION: In a method for analyzing a nucleic acid sequence of a sample by a computer, the computer analyzes gene mutation of a nucleic acid sequence on the basis of sequence information obtained by reading the nucleic acid sequence by a sequencer, retrieves a first medicine approved by at least one country as having a response in patients of a prescribed disease having prescribed mutation and an unapproved second medicine about at least one discovered gene mutation on the basis of at least one gene mutation discovered by the analysis, and generates a report displaying a first analysis result about the first medicine and a second analysis result about the second medicine in a discriminable manner on the basis of retrieval results.SELECTED DRAWING: Figure 44
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an analytical method for analyzing a nucleic acid sequence of a sample, an information processing device for analyzing a nucleic acid sequence of a sample, and a report providing method for providing a report including the analysis results of the nucleic acid sequence. [Background technology]

[0002] With recent advances in genetic testing technology, there are growing expectations for personalized medicine, in which a patient's genetic sequence is analyzed and an appropriate treatment plan is selected for each patient, taking into account characteristics such as the patient's genetic background, physiological state, and disease state.

[0003] In recent years, gene panel testing has emerged that uses next-generation sequencers to comprehensively examine abnormalities in multiple genes, and this technology is expected to play an important role in personalized medicine.

[0004] Recently, companion diagnostics (CDx), which predict the efficacy of a given drug, have been attracting attention. It is expected that CDx will be performed using the results of comprehensively examining abnormalities in multiple genes by gene panel testing.

[0005] Patent document 1 describes a system that determines whether genes, gene-expressed proteins, etc. are altered compared to a normal reference, and identifies drug therapies that can interact with the altered genes, gene-expressed proteins, etc. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] JP 2015-200678 A Summary of the Invention [Problem to be solved by the invention]

[0007] However, in the system described in Patent Document 1, it is difficult for medical institutions and medical professionals to determine whether the results of gene mutations provided by testing institutions that have performed gene panel tests approved for use in CDx applications are related to CDx.

[0008] In particular, in recent gene panel tests, abnormalities in multiple genes are comprehensively examined at the same time, so the results of gene panel tests contain a great deal of information. On the other hand, not all of the multiple genes tested are subject to CDx, and CDx is only applicable when a specific abnormality is detected in a specific gene. Even if an abnormality in the same gene is detected, the detection result of the genetic abnormality is not subject to CDx depending on the type of disease. Therefore, a very high level of expertise is required for medical professionals who look at gene panel tests to distinguish gene mutations that can actually be applied to companion diagnostics from the many genetic information contained in the test results and to determine the treatment policy and drugs to be used that are effective for the mutation.

[0009] One aspect of the present invention aims to provide an analysis method for analyzing the nucleic acid sequence of a sample by a computer, which can easily identify gene mutations applicable to CDx from the results of a gene panel test, an information processing device for analyzing the nucleic acid sequence of a sample, and a report providing method for providing a report including the analysis results of the nucleic acid sequence. [Means for solving the problem]

[0010] In order to solve the above problems, an analytical method according to aspect 1 of the present invention is a method for analyzing the nucleic acid sequence of a sample by a computer, in which the computer analyzes genetic mutations in the nucleic acid sequence based on sequence information obtained by reading the nucleic acid sequence by a sequencer, searches for a first drug that is approved in at least one country as being effective in patients with a specified disease having a specified mutation based on at least one of the genetic mutations discovered by the analysis, and a second unapproved drug related to the at least one of the discovered genetic mutations, and generates a report in which a first analysis result related to the first drug and a second analysis result related to the second drug are displayed in a distinguishable manner based on the results of the search.

[0011] In the analysis method according to aspect 2 of the present invention, in the first aspect, the computer may generate the report in which the first analysis result and the second analysis result are displayed in different areas.

[0012] In the analysis method according to aspect 3 of the present invention, in aspect 1 or 2, the computer may generate the report displaying information regarding the first analysis result indicating that the analysis result relates to companion diagnosis.

[0013] In the analysis method according to aspect 4 of the present invention, in any one of aspects 1 to 3, the computer may generate the report including information indicating that the genetic mutation related to companion diagnosis was not detected if the first drug was not searched for.

[0014] In the analysis method according to aspect 5 of the present invention, in any one of aspects 1 to 4, the computer may generate the report including information about the second drug that has been shown to be effective against a disease other than the specified disease.

[0015] In the analysis method according to aspect 6 of the present invention, in any one of aspects 1 to 5, the computer may generate the report in which the page on which the first analysis result is displayed and the page on which the second analysis result is displayed are different.

[0016] An information processing device according to aspect 7 of the present invention is an information processing device that analyzes the nucleic acid sequence of a sample, and includes: a mutation identification unit that analyzes genetic mutations in the nucleic acid sequence based on sequence information obtained by reading the nucleic acid sequence with a sequencer; a drug search unit that searches for a first drug that is approved in at least one country as being effective for patients with a specified disease having a specified mutation based on at least one of the genetic mutations discovered by the analysis, and a second unapproved drug related to the at least one of the discovered genetic mutations; and a report generation unit that generates a report in which a first analysis result related to the first drug and a second analysis result related to the second drug are displayed in a distinguishable manner based on the results of the search.

[0017] An information processing device according to aspect 8 of the present invention is the same as in aspect 7, wherein the report creation unit generates the report in which the first analysis result and the second analysis result are displayed in different areas.

[0018] In an information processing device according to aspect 9 of the present invention, in aspect 7 or 8, the report creation unit may generate the report displaying information regarding the first analysis result indicating that the analysis result relates to companion diagnosis.

[0019] An information processing device according to aspect 10 of the present invention is, in any one of aspects 7 to 9, the report creation unit of the information processing device may generate the report including information indicating that the genetic mutation related to companion diagnosis was not detected if the first drug is not searched for.

[0020] In the information processing device of aspect 11 of the present invention, in any of aspects 7 to 10, the report generation unit may generate the report including information about the second drug that has been shown to be effective against a disease other than the specified disease.

[0021] An information processing device according to aspect 12 of the present invention, in any of aspects 7 to 11, may be configured such that the report generation unit generates the report in which the page on which the first analysis result is displayed and the page on which the second analysis result is displayed are different.

[0022] A report providing method according to aspect 13 of the present invention is a method of providing a report including analysis results of a nucleic acid sequence of a sample by an information processing system, wherein the information processing system receives a request for analysis of the nucleic acid sequence of the sample derived from a patient suffering from a disease, and provides the report including the analysis results of the nucleic acid sequence read by a sequencer to the source of the analysis request, and the report displays a first analysis result for the first drug and a second analysis result for the second drug in a distinguishable manner based on the results of a search for a first drug that is approved in at least one country as being effective for patients with a specified disease having a specified mutation based on at least one genetic mutation discovered by the analysis, and a second unapproved drug related to the at least one genetic mutation discovered.

[0023] A report providing method according to a fourteenth aspect of the present invention is based on the thirteenth aspect, and the report may display the first analysis result and the second analysis result in different areas.

[0024] A report providing method according to aspect 15 of the present invention, in aspect 13 or 14, may further include information regarding the first analysis result indicating that the analysis result relates to companion diagnosis.

[0025] In a report providing method according to aspect 16 of the present invention, in any one of aspects 13 to 15, the report may include information indicating that the genetic mutation related to companion diagnosis was not detected if the first drug was not detected.

[0026] In a report providing method according to aspect 17 of the present invention, in any of aspects 13 to 16, the report may include information regarding the second drug that has been shown to be effective against a disease other than the specified disease.

[0027] A report providing method according to aspect 18 of the present invention is based on any one of aspects 13 to 17, wherein the report displays the first analysis result and the second analysis result on different pages. Effect of the Invention

[0028] According to the present invention, a specific mutation applicable to CDx can be easily identified from the results of gene panel testing. [Brief description of the drawings]

[0029] [Figure 1] 11 is a flowchart showing an example of the flow of a report creation process in the analysis method according to one embodiment of the present invention. [Diagram 2] 1 is a diagram showing an example of a system configuration including an information processing device that creates a report by an analysis method according to an embodiment of the present invention, and a sequencer that provides sequence information to the information processing device. [Diagram 3] 1 is a diagram showing an example of the configuration of a gene analysis system including an information processing device according to an embodiment of the present invention. [Figure 4] FIG. 2 is a sequence diagram showing an example of main processes performed in the gene analysis system. [Diagram 5] FIG. 2 is a diagram illustrating an example of a data structure of data stored in a management server. [Figure 6] FIG. 1 illustrates an example of a configuration of an information processing device. [Figure 7] 13 is a flowchart showing an example of a process flow for accepting input of information related to a gene panel. [Figure 8] FIG. 1 shows an example of a GUI used for inputting information regarding a gene panel. [Figure 9] FIG. 2 is a diagram showing an example of a data structure of a gene panel related information database. [Figure 10] FIG. 13 shows another example of a GUI used for inputting information regarding a gene panel. [Figure 11] FIG. 13 is a diagram showing another example of a GUI used for inputting identification information for identifying a disease. [Figure 12] FIG. 13 shows an example of a GUI used when an operator updates information related to a gene panel. [Figure 13] FIG. 13 shows another example of a GUI used when an operator updates information related to a gene panel. [Figure 14] 1 is a flow chart showing an example of a process flow for analyzing a gene sequence of a sample. [Figure 15] 1 is a flowchart illustrating an example of a pretreatment procedure for analyzing the base sequence of a sample DNA by a sequencer. [Figure 16] 11 is a flowchart illustrating another example of a pretreatment procedure for analyzing the base sequence of a sample DNA by a sequencer. [Figure 17] 11 is a flowchart illustrating another example of a pretreatment procedure for analyzing the base sequence of a sample DNA by a sequencer. [Figure 18] 11 is a flowchart illustrating another example of a pretreatment procedure for analyzing the base sequence of a sample DNA by a sequencer. [Figure 19] FIG. 1 is a diagram illustrating an example of a quality control sample. [Figure 20] FIG. 2 is a diagram showing an example of a data structure of a gene panel related information database. [Figure 21] FIG. 1 shows a specific example of a quality control sample. [Figure 22]FIG. 1 is a diagram illustrating an example of the step (a) of fragmenting a sample, and the step (b) of providing an index sequence and an adaptor sequence. [Figure 23] FIG. 2 is a diagram illustrating an example of a hybridization process. [Figure 24] FIG. 1 is a diagram illustrating an example of a process for recovering a DNA fragment to be analyzed. [Diagram 25] 1 is a flowchart illustrating an example of a procedure for analyzing the base sequence of a sample DNA using a sequencer. [Figure 26] FIG. 1 is a diagram illustrating an example of a step of subjecting a DNA fragment to a flow cell. [Figure 27] FIG. 1 is a diagram illustrating an example of a process for amplifying a DNA fragment to be analyzed. [Figure 28] FIG. 1 is a diagram illustrating an example of a sequencing process. [Figure 29] 13 is a flowchart illustrating an example of a flow of analysis by the quality evaluation device. [Diagram 30] FIG. 2 is a diagram showing an example of a file format of read sequence information. [Diagram 31] FIG. 4A is a diagram for explaining alignment by a data adjustment unit, and FIG. 4B is a diagram showing an example of a format of the alignment result by the data adjustment unit. [Diagram 32] FIG. 1 is a diagram showing an example of the structure of a reference sequence database. [Diagram 33] FIG. 1 shows examples of known mutations that are incorporated into reference sequences (not representing wild-type sequences) contained in a reference sequence database. [Diagram 34] 11 is a flowchart illustrating an example of a detailed alignment process. [Diagram 35] FIG. 10A is a diagram showing an example of score calculation, and FIG. 10B is a diagram showing another example of score calculation. [Diagram 36] FIG. 13 is a diagram showing an example of the format of a result file generated by a mutation identification unit. [Figure 37] FIG. 2 is a diagram showing an example of the structure of a mutation database. [Figure 38] FIG. 2 is a diagram showing a detailed example of the structure of mutation information in a mutation database. [Figure 39] FIG. 13A is a table showing the correspondence between the genes to be analyzed and location information, and FIG. 13B is a diagram showing the state in which mutations that do not correspond to information on the gene panel have been excluded from the result file. [Diagram 40] 13 is a flowchart showing an example of a process in which a drug search unit generates a list of drugs related to mutations. [Diagram 41] FIG. 2 is a diagram illustrating an example of a data structure of a drug database. [Diagram 42] FIG. 2 is a diagram illustrating an example of a data structure of a drug database. [Diagram 43] 13 is a flowchart showing an example of a process in which a drug search unit generates a list including information about drugs related to mutations. [Diagram 44] 13 is a flowchart showing an example of a process for determining whether or not there is a drug that may be used off-label based on information obtained by a drug search unit searching a drug database, and generating a list including the determination results. [Figure 44A] FIG. 13 is a diagram showing an example of a label attached to a container that contains a sample. [Figure 44B] FIG. 11 is a diagram showing another example of a label attached to a container that contains a sample. [Diagram 45] FIG. 2 is a diagram illustrating an example of a data structure of a drug database. [Diagram 46] FIG. 13 shows another example of a GUI used for inputting information regarding a gene panel. [Figure 47] FIG. 2 is a diagram illustrating an example of a data structure of a CDx information database. [Figure 48] 13 is a flowchart showing an example of a process in which a report creation unit creates a report including auxiliary information regarding the efficacy of a predetermined drug. [Figure 49] 13 is a flowchart showing another example of a process in which the report creation unit creates a report including auxiliary information regarding the efficacy of a predetermined drug. [Figure 50]13 is a flowchart showing an example of a process in which the report creation unit creates a report including auxiliary information regarding the efficacy of CDx depending on whether the gene panel used is CDx-targeted or not. [Figure 51] 13 is a flowchart showing another example of a process in which the report creation unit creates a report including auxiliary information regarding the efficacy of a predetermined drug. [Figure 52] FIG. 13 is a diagram illustrating an example of a report to be created. [Diagram 53] FIG. 13 is a diagram illustrating an example of a report to be created. [Figure 54] FIG. 13 is a diagram illustrating an example of a report to be created. [Figure 55] FIG. 13 is a diagram illustrating an example of a report to be created. [Figure 56] FIG. 13 is a diagram illustrating an example of a report to be created. [Figure 57] FIG. 13 is a diagram illustrating an example of a report to be created. [Figure 58] FIG. 13 is a diagram illustrating an example of a report to be created. [Figure 59] FIG. 13 is a diagram illustrating an example of a report to be created. [Figure 60] FIG. 13 is a diagram illustrating an example of a report to be created. [Figure 61] This is an example of a GUI that is displayed when a testing institution logs into a genetic analysis system. [Figure 62] FIG. 13 is a diagram showing an example of a report created when the contract type of a testing institution does not include CDx use. [Figure 63] FIG. 13 is a diagram illustrating an example of a quality evaluation index. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] [Embodiment 1] An analysis method according to one embodiment of the present invention is an analysis method that uses a computer to analyze the nucleic acid sequence of a sample collected from a subject. In this analysis method, a predetermined mutation (e.g., a gene mutation to be subjected to CDx) is identified based on sequence information read from the nucleic acid sequence, and a report is created that displays information related to the efficacy of a predetermined drug for a subject having the predetermined mutation according to a disease corresponding to the sample. First, an overview of this analysis method will be described with reference to Fig. 1. Fig. 1 is a flowchart showing an overview of the process flow of an information processing device 1 that executes an analysis method according to one embodiment of the present invention.

[0031] The information processing device 1 is a computer that executes the analysis method according to one embodiment of the present invention. FIG. 2 is a diagram showing an example of a system configuration including an information processing device 1 that creates a report by the analysis method according to one embodiment of the present invention, and a sequencer 2 that provides sequence information to the information processing device 1. As shown in FIG. 2, the information processing device 1 analyzes the sequence information generated by the sequencer 2 and analyzes the presence or absence of genetic abnormalities. The sequence information generated by the sequencer 2 is stored, for example, in an information storage medium connected to the sequencer 2, and the information processing device 1 acquires the sequence information from the information storage medium. The information processing device 1 may receive the sequence information read by the sequencer 2 via a communication line.

[0032] Here, “read sequence information” refers to the polynucleotide sequence obtained by sequencing, and “sequence information” refers to information on the read sequence output by the sequencer 2.

[0033] "Gene" includes a genomic sequence from a start codon to a stop codon, an mRNA generated from a genomic sequence, and a promoter region on a genome. "Gene mutation" means at least one of a gene polymorphism, a substitution, and a mutation such as InDel. "InDel (insertion and / or deletion)" means a gene mutation including an insertion, a deletion, or both an insertion and a deletion. Gene "polymorphism" includes SNV (Single Nucleotide Variant, single nucleotide polymorphism), VNTR (Variable Nucleotide of Tandem Repeat, repetitive sequence polymorphism), and STRP (Short Tandem Repeat Polymorphism, microsatellite polymorphism).

[0034] First, in step S1, the information processing device 1 confirms whether or not a predetermined gene mutation of the CDx target is detected based on the sequence information of the nucleic acid sequence of the sample. Next, in step S2, the information processing device 1 confirms whether or not the sample is a predetermined disease sample. For example, the information processing device 1 confirms whether or not the disease associated with the sample is a predetermined disease target of CDx in relation to the detected predetermined gene mutation. If the sample is a predetermined disease sample (YES in step S2), in step S3, the information processing device 1 creates a report including information on the efficacy of a predetermined drug associated with the predetermined gene mutation for the subject (hereinafter, may be simply referred to as "auxiliary information"). On the other hand, in the case of NO in steps S1 and S2, in step S4, the information processing device 1 creates a report that can determine that a gene mutation of the CDx target was not detected.

[0035] "Specified drugs" refers to drugs that can be used for companion diagnostics (CDx), etc. Drugs that can be used for CDx are generally defined as drugs to identify subjects (e.g., patients) who are more likely to benefit from treatment, drugs to identify subjects who are at high risk of developing specific side effects, drugs to optimize dosage or to appropriately determine when to discontinue administration, etc.

[0036] By employing this analysis method, the information processing device 1 can create a report including auxiliary information on the efficacy of a specific drug in response to the detection of a specific gene mutation in a sample of a specific disease. For example, the information processing device 1 creates a report that displays information related to the efficacy of a drug applicable to companion diagnosis (CDx) in response to the type of disease in the results of a panel test using a gene panel that can collectively analyze multiple abnormalities in multiple genes related to multiple diseases.

[0037] Reports created in this way make it easy to identify gene mutations applicable to CDx, even in the results of gene panel tests that comprehensively analyze multiple gene abnormalities. Providing such reports to medical institutions and other organizations will make it possible to more effectively use drugs that are relevant to the efficacy of drugs applicable to CDx based on the detection of gene mutations, and to provide personalized medicine.

[0038] Hereinafter, one embodiment of the present invention will be described in more detail.

[0039] (Application example of gene analysis system 100) First, an overview of a gene analysis system 100 including an information processing device 1 according to one embodiment of the present invention will be described with reference to Fig. 3. Fig. 3 is a diagram showing an example of the configuration of the gene analysis system 100 including the information processing device 1 according to one embodiment of the present invention. The gene analysis system 100 is a system that analyzes gene sequence information, and includes the information processing device 1, a sequencer 2, and a management server 3.

[0040] The genetic analysis system 100 shown in Figure 3 is applied to an analysis system management institution 130 that manages all analyses performed at the testing institution 120, and to the testing institution 120 that analyzes samples provided in response to analysis requests from medical institutions 210 and provides the analysis results to the medical institutions 210.

[0041] The testing institution 120 is an institution that tests and analyzes samples provided by the medical institution 210, creates a report based on the analysis results, and provides the report to the medical institution 210. In the example shown in Fig. 3, the testing institution 120 is equipped with a sequencer 2, an information processing device 1, and the like, but is not limited to this. For example, the testing institution 120 may be configured to include a facility in which the information processing device 1 is installed and another facility in which the sequencer 2 is installed.

[0042] The analysis system management institution 130 is an institution that manages all analyses performed in each testing institution 120 that uses the gene analysis system 100. The analysis system management institution 130 may be the same institution as the testing institution 120.

[0043] The medical institution 210 is an institution where doctors, nurses, pharmacists, etc. perform medical procedures such as diagnosis, treatment, and dispensing for patients, and examples thereof include hospitals, clinics, and pharmacies.

[0044] Although FIG. 3 illustrates an example in which the testing institution 120 and the medical institution 210 are separate institutions, the genetic analysis system 100 can also be suitably used in facilities in which the testing institution 120 and the medical institution 210 are integrated, such as a university hospital.

[0045] (Processing in an example where the gene analysis system 100 is applied) Next, the process flow in an application example of the gene analysis system 100 shown in Fig. 3 will be described in more detail with reference to Fig. 4. Fig. 4 is a sequence diagram showing an example of main processes performed in the gene analysis system 100. Note that the processes shown in Fig. 4 are only a part of the processes performed at each institution.

[0046] <Application for and start of use of the gene analysis system> First, the testing institution 120 that wishes to use the genetic analysis system 100 introduces the information processing device 1. Then, the testing institution 120 applies for the use of the genetic analysis system 100 to the analysis system management institution 130 (step S101). S101 can be omitted. For example, when the analysis system management institution 130 is the same as the testing institution 120, S101 is omitted.

[0047] The testing institution 120 and the analysis system management institution 130 can conclude a desired contract in advance regarding the use of the gene analysis system 100 from among a plurality of contract types. For example, the contract type may be selected from a plurality of contract types that differ in the service content provided by the analysis system management institution 130 to the testing institution 120, the method of determining the system usage fee that the analysis system management institution 130 charges the testing institution 120, and the method of paying the system usage fee. The management server 3 of the analysis system management institution 130 specifies the content of the contract concluded with the testing institution 120 in response to an application from the testing institution 120 (step S102). S102 can be omitted. For example, when the analysis system management institution 130 is the same as the testing institution 120, S102 is omitted.

[0048] Next, the management server 3 managed by the analysis system management institution 130 assigns an inspection institution ID to the information processing device 1 of the contracted inspection institution 120, and starts providing various services (step S103). S103 can be omitted. For example, when the analysis system management institution 130 is the same as the inspection institution 120, S103 is omitted. When the analysis system management institution 130 is the same as the inspection institution 120, the inspection institution ID and various services are managed by the inspection institution 120 itself.

[0049] The information processing device 1 receives programs, information, etc. for controlling gene sequence analysis results and reports based on the analysis results from the management server 3. This enables the testing institution 120 to receive various services from the analysis system management institution 130. The information processing device 1 can then output analysis results and reports that match the input information on the gene panel. When the analysis system management institution 130 is the same as the testing institution 120, programs, information, etc. for controlling gene sequence analysis results and reports based on the analysis results are managed by the testing institution 120 itself.

[0050] A gene panel often includes a set of reagents such as primers and probes. The gene panel may be used to analyze polymorphisms such as mutations, single nucleotide polymorphisms (SNPs), and copy number polymorphisms (CNVs) that have occurred in gene sequences. The gene panel may also be used to output information on the amount of mutations, etc., in the entire gene being analyzed (also called tumor mutation burden, etc.) or to calculate methylation frequency.

[0051] In this specification, the term "gene panel" refers to a gene panel capable of simultaneously analyzing multiple abnormalities in multiple genes and testing samples for multiple diseases. Such a gene panel is also called a "multi-panel" or "large panel" and is a gene panel that analyzes genes related to multiple diseases. In such a gene panel, the base sequence read from an exon region having a base length of 10 Mb (10 million bases) or more is the analysis target.

[0052] <Analysis request to testing agency 120> At the medical institution 210, a doctor or the like collects samples such as tissue and blood from the affected area of ​​the subject as necessary. When requesting the testing institution 120 to analyze the collected samples, for example, an analysis request is transmitted from the communication terminal 5 provided at the medical institution 210 (step S105). When requesting the testing institution 120 to analyze the samples, the medical institution 210 provides the testing institution 120 with a sample ID assigned to each sample together with the analysis request. The sample ID assigned to each sample associates each sample with information about the subject from whom each sample was collected (e.g., patient ID, etc.) and identification information for identifying the subject's disease (e.g., disease name and disease ID), etc. Note that the medical institution 210 may also transmit the subject ID and disease ID together with the sample ID to the testing institution 120.

[0053] In the following, an example will be described in which the medical institution 210 requests the testing institution 120 to perform an analysis of a panel test. Note that the panel test is not limited to a clinical test, but also includes a test for research purposes.

[0054] It should be noted that, as used herein, the term "subject" refers to a human in the examples herein, however, the concepts of the present invention can be applied to genomes derived from any organism, including animals, other than humans, and are useful in fields such as medicine, veterinary medicine, and animal science.

[0055] When a genetic panel test is requested from the medical institution 210, a desired genetic panel may be specified. Therefore, the analysis request transmitted from the medical institution 210 in step S105 of Fig. 4 may include information related to the genetic panel. Here, the information related to the genetic panel may be any information that can be used to identify the genetic panel, and may be, for example, the name of the genetic panel and the names of the genes to be analyzed in the panel test.

[0056] <Analysis at testing institution 120> The information processing device 1 receives the analysis request from the medical institution 210 (S106). Furthermore, the information processing device 1 receives the sample from the medical institution 210 that is the sender of the analysis request.

[0057] There are multiple gene panels that can be used in the analysis requested by the medical institution 210 to the testing institution 120, and the gene group to be analyzed is determined for each gene panel. The testing institution 120 can also use multiple gene panels according to the purpose of the analysis. That is, a first gene panel can be used to analyze a first gene group to be analyzed for a first sample provided by the medical institution 210, and a second gene panel can be used to analyze a second gene group to be analyzed for a second sample.

[0058] The information processing device 1 receives an input of information about a gene panel to be used for analyzing a sample from an operator (step S107).

[0059] At the testing facility 120, the received sample is pre-processed using a gene panel, and then sequenced using the sequencer 2 (step S108).

[0060] In addition, in addition to sequencing of normal samples, the testing institution 120 performs quality control by pre-processing a specified quality control sample corresponding to the gene panel using a gene panel and sequencing using sequencer 2 (step S108).

[0061] When quality control samples are subjected to genetic testing such as preprocessing, sequencing, and sequence analysis, the results are used as an indicator of the quality of the panel test.

[0062] One or more quality control samples may be associated with each gene panel, for example, a corresponding quality control sample may be prepared in advance for each gene panel. The quality control sample may be measured alone or together with a sample provided by the medical institution 210.

[0063] Here, the quality control sample is a sample for quality control used in a genetic test for testing a first type of genetic mutation and a second type of genetic mutation different from the first type. The "quality control sample" is a preparation containing a first standard gene having a first type of genetic mutation and a second standard gene having a second type of genetic mutation.

[0064] The pre-processing may include a process of fragmenting genes such as DNA contained in a sample and recovering the fragmented genes. Moreover, the sequencing includes a process of reading the sequence of one or more DNA fragments to be analyzed that are recovered in the pre-processing. The sequence information read by the sequencing by the sequencer 2 is input to the information processing device 1 as lead sequence information. The information processing device 1 may be configured to obtain the lead sequence information from the sequencer 2 via a communication line. For example, the sequencer 2 may be installed in the medical institution 210 and the analysis system management institution 130, and the information processing device 1 may obtain the lead sequence information read by the sequencer 2 via the communication line 4 (network). According to this configuration, even in the testing institution 120 where the sequencer 2 is not installed, it is possible to obtain the lead sequence information from an external source and create a report including auxiliary information that is information regarding the efficacy of a drug for the subject having a gene mutation.

[0065] Pretreatment may also include a process for fragmenting genes, such as DNA, contained in the sample and quality control sample, and recovering the fragmented genes.

[0066] The read sequence refers to the polynucleotide sequence obtained by sequencing, and indicates the sequence output from sequencer 2.

[0067] Sequencing includes a process of reading the sequences of one or more DNA fragments to be analyzed that were collected in the preprocessing. Sequence information read by sequencing using the sequencer 2 is input to the information processing device 1 as read sequence information.

[0068] The sequencer 2 may output read sequence information including a quality score, which is a quality evaluation index for the gene sequence reading process, to the information processing device 1. The sequencer 2 may also output a cluster concentration, which is a quality evaluation index for the amplification process of the DNA fragment to be analyzed, to the information processing device 1. The "quality score" and "cluster concentration" will be described later.

[0069] The information processing device 1 acquires the read sequence information from the sequencer 2 and analyzes the gene sequence (step S109).

[0070] The quality control sample is also processed in the same manner as in the panel testing of samples from the medical institution 210, and the genetic sequence information of the quality control sample is analyzed. Based on the results of analyzing the quality control sample, a quality evaluation index for evaluating the quality of the panel testing is generated.

[0071] Next, the information processing device 1 evaluates the quality of the panel inspection based on the quality evaluation index generated by the quality management unit 117 (step S110). Specifically, the information processing device 1 can evaluate the quality of each panel inspection based on a comparison result between the evaluation criteria set for each quality evaluation index stored in the quality evaluation criteria 126 in FIG. 6 and the generated quality evaluation index.

[0072] The information processing device 1 creates a report based on the analysis result in step S109 and the index generated based on the result of analyzing the quality control sample (step S111), and transmits the created report to the communication terminal 5 (step S112). The report may include, for example, data on the alignment result of the read sequence information, data on the results of the analysis by the information processing device 1 such as data on identified gene mutations, etc., and information on the quality of the panel test.

[0073] The created report may be printed by the testing institution 120, and for example, the testing institution 120 may send the created report to the medical institution 210 as a paper medium.

[0074] The information processing device 1 of the testing institution 120 that uses the genetic analysis system 100 notifies the management server 3 of information on the gene panel used in the analysis, information on the analyzed genes, the analysis results, and the quality evaluation index generated for the genetic test performed (step S114). S114 can be omitted. For example, if the analysis system management institution 130 is the same as the testing institution 120, S114 is omitted. In this case, the testing institution 120 itself manages the analysis results, quality evaluation index, etc.

[0075] The management server 3 acquires, for example, via the communication line 4, the testing institution ID, genetic panel ID, gene ID, and analysis results from the information processing device 1 of each testing institution 120 that uses the genetic analysis system 100. The management server 3 also stores the acquired testing institution ID, genetic panel ID, gene ID, analysis results, quality evaluation index, etc. in association with each other (step S115). S115 can be omitted. For example, if the analysis system management institution 130 is the same as the testing institution 120, S115 is omitted. In this case, the testing institution 120 itself manages the analysis results, quality evaluation index, etc.

[0076] The testing institution ID is information that identifies the testing institution 120 that performs gene sequence analysis, and may also be an operator ID, which is identification information assigned to each operator belonging to the testing institution 120 that uses the information processing device 1.

[0077] The gene panel ID is identification information assigned to identify a gene panel used to analyze a gene to be analyzed. The gene panel ID assigned to a gene panel is associated with the name of the gene panel and the name of the company providing the gene panel.

[0078] The gene ID is identification information given to each gene to identify the gene to be analyzed.

[0079] The analysis results are information on the analysis status of gene sequence information. The analysis results may be, for example, the number of sequence analyses performed using a predetermined gene panel in the information processing device 1, the number of analyzed genes, or the cumulative number of identified gene mutations. Alternatively, the analysis results may be information on the amount of data processed in the analysis.

[0080] The management server 3 tally up the analysis results for each testing institution 120 for a predetermined period (e.g., any period such as a day, week, month, or year) and determines a system usage fee according to the tallying result and the contract type (step S116). The analysis system management institution 130 may bill the testing institution 120 for the determined system usage fee and request that the system usage fee be paid to the analysis system management institution 130. S116 can be omitted. For example, if the analysis system management institution 130 is the same as the testing institution 120, S116 is omitted.

[0081] (Configuration example of gene analysis system 100) The gene analysis system 100 is a system that analyzes gene sequence information, and includes at least an information processing device 1 and a management server 3. The information processing device 1 is connected to the management server 3 via a communication line 4 such as an intranet or the Internet.

[0082] (Sequencer 2) The sequencer 2 is a base sequence analyzer used to read the base sequence of genes contained in a sample.

[0083] The sequencer 2 according to this embodiment is preferably a next-generation sequencer that performs sequencing using next-generation sequencing technology, or a third-generation sequencer. Next-generation sequencers are a group of base sequence analyzers that have been developed in recent years, and have dramatically improved analytical capabilities by performing massive parallel processing of clonally amplified DNA templates or single DNA molecules in a flow cell.

[0084] Furthermore, the sequencing technology that can be used in this embodiment may be a sequencing technology that obtains multiple reads by reading the same region in duplicate (deep sequencing).

[0085] Examples of sequencing techniques that can be used in this embodiment include ion semiconductor sequencing, pyrosequencing, sequencing-by-synthesis using reversible dye terminators, sequencing-by-ligation, and sequencing by oligonucleotide probe ligation, which are sequencing techniques that can obtain a large number of reads per run. The present invention may also be applied to whole genome sequencing, which analyzes the base sequence of the entire genome, rather than the base sequence of a specific region. Whole genome sequencing is applied to a gene panel that analyzes genes related to multiple diseases, and is capable of reading base sequences from exon regions of 10 Mb (10 million bases) or more.

[0086] The sequencing primer used for sequencing is not particularly limited, and is appropriately set based on a sequence suitable for amplifying the target region. In addition, the reagent used for sequencing may be selected according to the sequencing technology and sequencer 2 used. The procedure from pretreatment to sequencing will be described later with a specific example.

[0087] (Management Server 3) Next, the data stored in the management server 3 will be described with reference to FIG. 5. FIG. 5 is a diagram showing an example of the data structure of the data stored in the management server 3. The analysis system management institution 130 determines the system usage fee to be charged to each testing institution based on each data shown in FIG. 5. The management server 3 receives information including information (e.g., testing institution ID) for identifying the testing institution 120 performing gene sequence analysis, information on the gene panel used, and information on the analysis status of the gene sequence (e.g., analysis results) from the information processing device 1 via the communication line 4. In addition, in FIG. 5, "gene panel A" is written as "A panel", "gene panel B" is written as "B panel", and the "gene panel ID" is written as "panel ID".

[0088] In data 3A shown in Fig. 5, the name of the testing institution using the genetic analysis system 100 is associated with a testing institution ID assigned to each testing institution. In data 3B shown in Fig. 5, the type of contract concluded between the analysis system management institution 130 and the testing institution 120, the services (e.g., available gene panels) provided to the testing institution that has concluded each contract, and the system usage fee are associated with each other.

[0089] For example, if a testing institution "P Institution" has concluded a contract for "Plan 1" with the analysis system management institution 130, the analysis system management institution 130 will bill the testing institution P for a usage fee according to the number of operations. The "number of operations" is, for example, the number of panel tests performed by the information processing device 1. When starting to use the genetic analysis system 100, the testing institution P logs into the genetic analysis system 100 using the testing institution ID and password of the testing institution P. The management server 3 can identify the name of the testing institution, the contract type, etc. based on the testing institution ID entered at the time of login.

[0090] "Plan 3" is a higher-level plan than "Plan 1" that includes the provision of auxiliary information that can be used for "CDx applications." Therefore, the cost of entering into a "Plan 3" contract may be higher than the cost of entering into a "Plan 1" contract.

[0091] For a testing institution that has concluded a contract for "Plan 3", CDx information necessary for creating a report including auxiliary information related to the efficacy of drugs applicable to companion diagnostics (CDx) is provided (see S104 in FIG. 4). For example, when a testing institution "Q institution" has concluded a contract for "Plan 3" with the analysis system management institution 130, the management server 3 identifies the testing institution name and contract type, etc. based on the testing institution ID entered when the testing institution Q logs into the gene analysis system 100, and provides the testing institution Q with auxiliary information related to the efficacy of drugs applicable to CDx. This allows the testing institution Q to provide the medical institution 210 with a report including auxiliary information related to the efficacy of drugs applicable to CDx.

[0092] Data 3C to 3E shown in FIG. 5 are analysis results relating to the number of operations performed, genes analyzed, and the total number of genetic mutations identified by the testing institution using the gene analysis system 100 during the period from August 1, 2017 to August 31, 2017. These analysis results are transmitted from the information processing device 1 to the management server 3 and stored in the management server 3. The analysis system management institution 130 determines the system usage fee to be charged to each testing institution based on this data of analysis results. The period for tallying up the results is not limited to the above, and may be any period such as a day, a week, a month, or a year.

[0093] When the analysis system management institution 130 determines the system usage fee, the system usage fee may be changed depending on whether the gene panel used in the test was provided by a company that provides (e.g., manufactures or sells) the gene panel. In this case, the management server 3 may store data 3F shown in Fig. 5. Data 3F shown in Fig. 5 associates the name of the company providing the gene panel, such as "Company A" or "Company B," with the gene panel ID and an agreement regarding the system usage fee (e.g., whether or not a system usage fee is required).

[0094] An example will be described in which "Institution P" has concluded a contract for "Plan 1" with the analysis system management institution 130, and the analysis results are as shown in FIG. 5. Institution P has conducted five tests using a gene panel (gene panel ID "AAA") provided by Company A, and ten tests using a gene panel (gene panel ID "BBB") provided by Company B. According to the data shown in FIG. 5, no system usage fee is required for the five tests using the gene panel provided by Company A. Therefore, the analysis system management institution 130 determines the system usage fee for Institution P, excluding the number of tests using the gene panel provided by Company A.

[0095] (Configuration example of information processing device 1) 6 is an example of the configuration of the information processing device 1. The information processing device 1 is a device including a control unit 11 that acquires lead sequence information read by a sequencer 2 and information on a gene panel including a plurality of genes to be analyzed, and an output unit 13 that outputs an analysis result of the lead sequence information based on the information on the gene panel acquired by the control unit 11. The information processing device 1 can be configured using a computer. For example, the control unit 11 is a processor such as a CPU (Central Processing Unit), and the memory unit 12 is a hard disk drive.

[0096] The storage unit 12 also stores a program for sequence analysis, a program for generating a single reference sequence, and the like. The output unit 13 includes a display, a printer, a speaker, and the like. The input unit 17 includes a keyboard, a mouse, a touch sensor, and the like. A device having both the functions of an input unit and an output unit, such as a touch panel in which a touch sensor and a display are integrated, may also be used. The communication unit 14 is an interface for the control unit 11 to communicate with an external device.

[0097] The information processing device 1 includes a control unit 11 that controls each unit of the information processing device 1, a memory unit 12 that stores various data used by an analysis execution unit 110, an output unit 13, a communication unit 14, and an input unit 17. The control unit 11 includes an analysis execution unit 110 and a management unit 116. Furthermore, the analysis execution unit 110 includes a sequence data reading unit 111, an information selection unit 112, a data adjustment unit 113, a mutation identification unit 114, a quality control unit 117, a drug search unit 118, and a report creation unit 115. The memory unit 12 stores a gene panel related information database 121, a reference sequence database 122, a mutation database 123, a drug database 124, and an analysis result log 151.

[0098] Even if a different gene panel is used for each analysis, the information processing device 1 creates a report including the analysis results corresponding to the gene panel used. An operator using the gene analysis system 100 can analyze the results of the panel test using a common analysis program regardless of the type of gene panel and create a report. This eliminates the hassle of having to use different analysis programs for each gene panel or make special settings for the analysis program for each gene panel when performing a panel test, improving the convenience for the operator.

[0099] When an operator of the information processing device 1 inputs information regarding a gene panel from the input unit 17, the information selection unit 112 refers to the gene panel related information database 121 and controls the algorithm of the analysis program so that the analysis program performs analysis of the genes to be analyzed in accordance with the input information regarding the gene panel.

[0100] Here, the information regarding the gene panel may be any information that identifies the gene panel used in the measurement by the sequencer 2, such as the gene panel name, the names of the genes being analyzed in the gene panel, and the gene panel ID.

[0101] Based on the information on the gene panel input from the input unit 17, the information selection unit 112 changes the analysis algorithm for performing an analysis corresponding to the genes to be analyzed in the gene panel indicated by the information on the gene panel.

[0102] The information selection unit 112 outputs an instruction based on the information on the gene panel to at least one of the data adjustment unit 113, the mutation identification unit 114, the drug search unit 118, and the report creation unit 115. By adopting this configuration, the information processing device 1 can output the analysis result of the lead sequence information based on the input information on the gene panel.

[0103] In other words, the information selection unit 112 is a functional block that acquires information regarding a gene panel including multiple genes to be analyzed, and controls the analysis results of the read sequence information to be output from the output unit 13 based on the acquired information regarding the gene panel.

[0104] When genes contained in various samples are analyzed by the testing institution 120 that performs the panel test, various gene panels are used according to the gene group to be analyzed for each sample.

[0105] That is, the information processing device 1 can acquire first read sequence information read using a first gene panel for analyzing a first group of genes to be analyzed from a first sample, and second read sequence information read using a second gene panel for analyzing a second group of genes to be analyzed from a second sample.

[0106] The information processing device 1 is equipped with an information selection unit 112, so that it can appropriately output the analysis results of the read sequence information, even when various combinations of target genes are analyzed using various gene panels.

[0107] In other words, it is possible to appropriately output the analysis results of each lead sequence information by simply having the operator select information regarding the gene panel, without having to set up an analysis program to be used in analyzing the lead sequence information for each gene to be analyzed or perform the analysis.

[0108] For example, when the information selection unit 112 outputs an instruction based on information on a gene panel to the data adjustment unit 113, the data adjustment unit 113 performs an alignment process that reflects the information on the gene panel.

[0109] Depending on the information regarding the gene panel, the information selection unit 112 instructs the data adjustment unit 113 to limit the reference sequences (reference sequences incorporating wild-type genomic sequences and mutant sequences) used for mapping the read sequence information to only reference sequences related to genes corresponding to the information regarding the gene panel.

[0110] In this case, since the results of processing by the data adjustment unit 113 already reflect information about the gene panel, the information selection unit 112 does not need to output instructions based on information about the gene panel to the mutation identification unit 114, which performs processing following the processing by the data adjustment unit 113.

[0111] For example, when the information selection unit 112 outputs an instruction based on information on a gene panel to the mutation identification unit 114, the mutation identification unit 114 performs processing that reflects the information on the gene panel.

[0112] For example, the information selection unit 112 instructs the mutation identification unit 114 to limit the area of ​​the mutation database 123 referred to by the mutation identification unit 114 to only mutations related to the gene corresponding to the information on the gene panel, depending on the information on the gene panel. This allows the information on the gene panel to be reflected in the results of processing by the mutation identification unit 114.

[0113] (Enter gene panel information) Here, the process of accepting input of information on a gene panel shown in step S107 of Fig. 4 will be described with reference to Fig. 7. Fig. 7 is a flow chart showing an example of the flow of the process of accepting input of information on a gene panel.

[0114] Here, a configuration will be described as an example in which the control unit 11 displays a GUI for inputting information about a gene panel on the input unit 17, and the operator inputs information about the gene panel. Here, a configuration will be described in which the input unit 17 is equipped with a touch panel that allows the operator to perform an input operation on the GUI presented to the operator.

[0115] First, the control unit 11 of the information processing device 1 causes the input unit 17 to display a GUI for allowing an operator to select information related to a gene panel. Based on an input operation by the operator to the GUI, information related to a gene panel is acquired (step S201).

[0116] The information selection unit 112 searches the gene panel related information database 121 based on information selected by the operator from among the information displayed as the GUI, and reads out information related to the gene panel corresponding to the selected information.

[0117] Furthermore, the information processing device 1 reads out information on the gene panel included in the analysis request received from the medical institution 210.

[0118] If the gene panel corresponding to the selected information is registered in the gene panel related information database 121 (YES in step S202) and the gene panel matches the gene panel included in the analysis request received from the medical institution 210 (YES in step S203), the information selection unit 112 accepts the input. Then, the information selection unit 112 displays a message to the input unit 17 that the input gene panel is available (step S204).

[0119] On the other hand, if the genetic panel corresponding to the selected information is not registered in the genetic panel related information database 121, i.e., if an unregistered genetic panel is selected (NO in step S202), the information selection unit 112 displays a message on the input unit 17 to the effect that the input genetic panel cannot be used (step S205), and prohibits analysis by the information processing device 1.

[0120] In this case, a message informing of an error may be displayed instead of the message indicating that the gene panel is unavailable. Such a message may be, for example, a message saying "The selected gene panel is not registered," or may further include a message prompting re-input, such as "Please re-input information about the gene panel."

[0121] Furthermore, if the genetic panel corresponding to the selected information does not match the genetic panel included in the analysis request received from the medical institution 210 (NO in step S203), the information selection unit 112 displays a message on the input unit 17 to the effect that the input genetic panel cannot be used (step S205), and prohibits analysis by the information processing device 1.

[0122] In this case, a message informing the user of the error may be displayed instead of the message indicating that the gene panel is unavailable. Such a message may be, for example, a message saying "The selected gene panel is different from the order" or may further include a message prompting the user to re-enter information about the gene panel, such as "Please re-enter information about the gene panel."

[0123] Such processing prevents sequencing using an inappropriate gene panel or performing unnecessary analytical operations, thereby eliminating unnecessary use of gene panels and unnecessary operation of the genetic analysis system 100.

[0124] (Example of GUI used to input information about gene panels) Next, some examples of GUIs that allow an operator to input information related to a gene panel will be described with reference to Fig. 8. Fig. 8 is a diagram showing an example of a GUI used for inputting information related to a gene panel.

[0125] As shown in FIG. 8, a list of gene panel names such as "xxxxx" and "yyyyy" may be displayed on the GUI as information relating to the gene panel, and the operator may be allowed to select a desired gene panel from the gene panels shown in the list.

[0126] The list of gene panel names displayed on the GUI is displayed based on the gene panel names of gene panels to which gene panel IDs have been assigned and which are registered in the gene panel related information database 121 .

[0127] 8 shows a state where "gene panel 2 (gene panel name: "yyyyy")" has been selected by the operator. The information selection unit 112 searches the gene panel related information database 121 using the gene panel ID associated with the selected gene panel name "yyyyy" as a key to acquire information on the gene panel corresponding to the input gene panel name.

[0128] (Gene Panel Related Information Database 121) Next, data stored in the gene panel related information database 121 referred to by the information selecting unit 112 when information related to a gene panel is input via the input unit 17 will be described with reference to Fig. 9. Fig. 9 is a diagram showing an example of the data structure of the gene panel related information database 121.

[0129] The gene panel related information database 121 stores, for each gene panel, the names of genes that can be analyzed and gene IDs assigned to each gene, as in data 121A shown in Fig. 9. The gene panels "A panel," "B panel," and "C panel" are gene panels (so-called "large panels") that can collectively analyze multiple abnormalities in multiple genes related to multiple diseases.

[0130] In addition, the gene panel related information database 121 stores the names of selectable gene panels, gene panel IDs assigned to each gene panel, gene IDs (related gene IDs) of genes that each gene panel is analyzing, and CDx flags in association with each other, as shown in data 121B in FIG. 9. The CDx flag is a flag indicating whether or not a gene panel is a CDx target. A CDx target gene panel is a gene panel capable of detecting gene mutations that are CDx targets. Each gene panel may also be associated with information regarding whether or not its use has been approved by a public institution (e.g., the Ministry of Health, Labor and Welfare of Japan, etc.).

[0131] As shown in FIG. 8, when an operator is asked to select a desired gene panel from among the gene panels presented in the GUI, the information selection unit 112 refers to the gene panel related information database 121 to extract the gene panel ID and related gene IDs associated with the selected gene panel name.

[0132] As shown in FIG. 10, when a gene to be analyzed is selected from among the gene names presented in the GUI, the information selection unit 112 refers to the gene panel related information database 121 to extract gene IDs associated with the selected gene name and gene panel IDs of gene panels that include these gene IDs in their related gene IDs.

[0133] When performing a panel test using a gene panel capable of simultaneously analyzing multiple abnormalities in multiple genes related to multiple diseases, it is possible to input which disease each sample is related to. For example, as shown in FIG. 11, identification information for identifying a disease may be selected from a list of disease names presented on a GUI. The information selection unit 112 outputs the selected and input disease name (or disease ID) to the data adjustment unit 113, the mutation identification unit 114, the drug search unit 118, the quality control unit 117, the report creation unit 115, and the like. The information selection unit 112 may be configured to automatically obtain the disease name and disease ID of the subject associated with each sample ID based on the sample ID.

[0134] <Update of gene panel related information database 121> Here, updating of information stored in the genetic panel related information database 121 will be described with reference to Fig. 12 and Fig. 13. Fig. 12 and Fig. 13 are diagrams showing examples of GUIs used when an operator updates the genetic panel related information database 121.

[0135] The information stored in the gene panel related information database 121 can be updated by an update patch provided to the testing institution 120 by the analysis system management institution 130 .

[0136] The analysis system management institution 130 may provide an update patch only to the testing institution 120 that has paid the system usage fee. For example, the analysis system management institution 130 may notify the testing institution 120 that an update patch is available and that payment of the system usage fee is a condition for providing the update patch. By notifying the testing institution 120 in this manner, the testing institution 120 can be appropriately prompted to pay the system usage fee.

[0137] When updating multiple genes at once, a field for inputting a "registered file name" may be displayed, and a file name containing gene names, such as "genes targeted for gene panel.csv," may be input into that field, as shown in Figure 12. In the example shown in Figure 12, this "genes targeted for gene panel.csv" contains multiple gene names, such as RET, CHEK2, PTEN, and MEK1.

[0138] When the "Register" button is pressed after the file name is input, a request to update information on the gene corresponding to the gene name included in the file is associated with the testing institution ID and transmitted to the management server 3 via the communication unit 14. The generation of this update request and the association with the testing institution ID may be configured to be performed by, for example, the control unit 11 in FIG.

[0139] The analysis system management institution 130 permits the information processing device 1 to download information including the gene ID assigned to the gene name included in the update request received by the management server 3 and the gene panel ID assigned to the gene panel that analyzes the gene.

[0140] Alternatively, when the operator updates the gene names by inputting them individually, a field for inputting the "gene name" may be displayed as shown in FIG. 13, and the operator may input the gene name, such as "FBXW7", in that field.

[0141] When the "Register" button is pressed after the gene name is input, a request to update information on the gene corresponding to the gene name is associated with the testing institution ID and transmitted to the management server 3 via the communication unit 14. The analysis system management institution 130 permits the information processing device 1 to download information including the gene ID assigned to the gene name included in the update request received by the management server 3 and the gene panel ID assigned to the gene panel that analyzes the gene.

[0142] The field in FIG. 12 for inputting the "registered file name" and the field in FIG. 13 for inputting the "gene name" may be configured to display input candidates as suggestions.

[0143] For example, information on the input candidates to be displayed is provided in advance from the management server 3 to the information processing device 1 and stored in the storage unit 12. Then, when a click operation on the GUI of the input field is detected, all updatable gene names may be presented as input candidates and the operator may select from among them, or updatable gene names that match a character string input by the operator may be presented as input candidates. Alternatively, for example, when the operator inputs "E" in the field for inputting "gene name" in FIG. 13, a list of updatable gene names such as "EGFR" and "ESR" may be displayed and the operator may select from the list. By presenting input candidates in this way, input errors by the operator can be prevented.

[0144] The gene panel related information database 121 may store the name of each gene, the gene ID of the gene, and the name of the protein encoded by the gene in association with each other.

[0145] In this case, even if the input character string is not a gene name but a protein encoded by the gene, the information selection unit 112 can refer to the gene panel related information database 121 to obtain the gene name and gene ID associated with the input protein name.

[0146] In addition, when a protein name is entered in the field for entering the "gene name" and the registration button is pressed, a GUI may be displayed that displays the gene name associated with the protein name and allows the operator to confirm that the gene name is correct.

[0147] (Management Department 116) The management unit 116 associates the analysis results including the number of times the analysis execution unit 110 has operated, the number of genes analyzed, and the total number of identified genes with the gene panel ID and gene ID, and stores them in the analysis results log 151 as needed. The management unit 116 reads out data including the analysis results from the analysis results log 151 at any frequency (e.g., daily, weekly, or monthly), associates the data with the testing institution ID, and transmits the data to the management server via the communication unit 14.

[0148] (Communications Department 14) The communication unit 14 enables the information processing device 1 to communicate with the management server 3 via the communication line 4. Data transmitted from the communication unit 14 to the management server 3 may include a testing institution ID, a gene panel ID, a gene ID, analysis results, an update request, etc. Furthermore, data received from the management server 3 may include information related to the gene panel, names of genes that can be updated, etc.

[0149] (Process flow for analyzing the gene sequence of a sample) Here, the flow of processing for analyzing the gene sequences of a sample and a quality control sample will be described with reference to Fig. 14. Fig. 14 is a flow chart showing an example of the flow of processing for analyzing the gene sequence of a sample.

[0150] First, in step S31 of Fig. 14, pre-processing is performed to analyze the sequence of the gene to be analyzed. The pre-processing includes processing from fragmenting genes such as DNA contained in the sample and the quality control sample to recovering the fragmented genes. Note that, when the sample provided by the medical institution 210 is tissue or blood, the pre-processing also includes processing to extract genes (e.g., DNA) from the tissue or blood.

[0151] Next, in step S32, the sequences of the genes contained in the pretreated sample and the quality control sample are read by the sequencer 2.

[0152] Specifically, step S32 is a step in which the sequences of one or more DNA fragments to be analyzed that are collected after pretreatment are read. The read sequence information includes the gene sequence read in this step. The one or more DNA fragments to be analyzed that are collected after pretreatment are sometimes called a "library."

[0153] Subsequently, when a quality control sample is measured, in step S33, the information processing device 1 analyzes the read gene sequence and specifies the presence or absence of a mutation in the sequence, the position of the mutation, the type of the mutation, etc. By analyzing the read gene sequence, the detected gene mutation is identified.

[0154] Next, in step S34, the quality management unit 117 generates a quality evaluation index for evaluating the quality of the panel inspection. The information processing device 1 may evaluate the quality of the performed panel inspection based on the generated quality evaluation index.

[0155] Finally, the information processing device 1 creates a report including the analysis results of the information related to the gene mutation identified in step S33, and information indicating the quality of the panel test, such as the quality evaluation index generated by the quality control unit 117 in step S34. The created report is provided to the medical institution 210.

[0156] The type of sequencer 2 that can be used in this embodiment is not particularly limited, and a sequencer that can analyze multiple analysis targets in one run can be suitably used. In the following, as an example, a sequencer (e.g., MySeq, HiSeq, NextSeq, etc.) from Illumina, Inc. (San Diego, CA) or a device that employs a method similar to that of an Illumina sequencer will be described.

[0157] Illumina's sequencers combine the Bridge PCR method with a technique called sequencing-by-synthesis, which allows them to amplify huge amounts of target DNA on a flow cell and sequence it while synthesizing it.

[0158] (a. Pretreatment) Next, the pre-processing procedure of step S31 in Fig. 14 will be described with reference to the flow shown in Fig. 15 to 18. Fig. 15 to 18 are a flowchart illustrating an example of the pre-processing procedure for analyzing the base sequence of a sample DNA by the sequencer 2.

[0159] When extracting DNA from each of a sample and a quality control sample for sequence analysis, first, DNA is extracted from a sample containing the gene to be analyzed and a quality control sample corresponding to the gene panel to be used (step 300 in Figures 15 to 18).

[0160] In this case, the DNA derived from the sample and the DNA derived from the quality control sample are each subjected to the processes from step S301 onwards.

[0161] By subjecting DNA extracted from quality control samples to the same processing as DNA extracted from samples, it is possible to generate quality assessment indices that are useful for assessing the quality of sequence analysis in panel testing.

[0162] It should be noted that the method of using the quality control sample is not limited to this. For example, as shown in Fig. 16, only DNA may be extracted from the quality control sample in step S300a, and the processes in and after step S301 may be carried out.

[0163] Alternatively, as shown in FIG. 17, a quality control sample containing a mutation and a quality control sample not containing a mutation may be prepared as quality control samples, and DNA may be extracted from these samples (step 300b).

[0164] By comparing the analysis results of DNA from quality control samples containing mutations with the analysis results of DNA from quality control samples not containing mutations, a quality evaluation index useful for evaluating the quality of sequence analysis in panel testing can be generated.

[0165] Alternatively, DNA may be extracted from a sample containing the gene of interest, a quality control sample containing the mutation, and a quality control sample not containing the mutation (step 300c), as shown in Figure 18. The sample containing the gene of interest may be a combination of a blood sample and a tumor cell sample.

[0166] In the processing from step S301 onwards, the DNA derived from the sample and the DNA derived from the quality control sample may be mixed and processed in step S301 onwards, rather than processing the DNA derived from the sample and the DNA derived from the quality control sample separately. This makes it possible to generate a more accurate quality evaluation index, since the conditions for both are the same in all processing from step S301 onwards. In addition, it is not necessary to use some of the lanes of the flow cell used in the sequencer 2 only for DNA fragments prepared from the quality control sample. This allows a limited number of lanes to be used effectively for DNA fragments derived from the sample containing the gene to be analysed.

[0167] In this case, it is desirable to use (1) a reagent for preparing a library by appropriately fragmenting the standard genes contained in the quality control sample and the genes to be analyzed in the panel test, and (2) a reagent containing an RNA bait for appropriately capturing each DNA fragment after fragmenting the standard genes contained in the quality control sample and the genes to be analyzed in the panel test.

[0168] (Quality control sample) In one embodiment, the quality control sample is a composition containing a plurality of standard genes. The quality control sample can be prepared by mixing a plurality of standard genes. A reagent in which these standard genes are mixed and contained in a single container can be provided to the testing institution 120 as a quality control sample. In addition, a plurality of standard genes may be contained in separate containers as a quality control sample and provided to the testing institution 120 in the form of a kit. The quality control sample may be in the form of a solution or a solid (powder). When the quality control sample is provided as a solution, an aqueous solvent known to those skilled in the art, such as water or TE buffer, can be used as the solvent.

[0169] The quality control sample will be described with reference to Fig. 19. Fig. 19 is a diagram for explaining an example of the quality control sample.

[0170] Figure 19(a) shows a list of genes that can be analyzed in a panel test using a gene panel. One or more genes in this list are associated as genes to be analyzed in the gene panel (see data 121B in Figure 9).

[0171] Figure 19 (b) and (c) show examples of mutation types to be detected in panel testing. The types of mutations to be detected include "SNV (single nucleotide polymorphism)," "Insertion," and "Deletion" (indicated as "InDel" in the figure), "CNV (copy number variation)," and "Fusion."

[0172] Quality control sample A1 corresponding to gene panel A contains at least two of the following standard genes: a standard gene containing SNV, a standard gene containing insertion, a standard gene containing deletion, a standard gene containing CNV, and a standard gene containing fusion. For example, quality control sample A1 contains, as standard genes, a partial sequence of gene A containing "SNV" relative to the wild type and a partial sequence of gene B containing "insertion" relative to the wild type.

[0173] FIG. 19(d) shows an example of the output of the analysis results of the genetic test using gene panel A and the analysis results of the quality control sample. In this example, the analysis results of gene panel A include GNA11, AKT1, and PIK3CA SNVs, EGFR long insertion and long deletion, SLC34A2 and ROS1 fusion gene, CCDC6 and RET fusion gene, MET gene amplification, MYC-N gene amplification, and MYC-C gene amplification. The quality control sample of gene panel A contains a standard gene containing a GNA11 SNV, a standard gene containing an AKT1 SNV, a standard gene containing a PIK3CA SNV, a standard gene containing an EGFR long insertion, a standard gene containing an EGFR long deletion, a standard gene containing a SLC34A2 and ROS1 fusion sequence, a standard gene containing a CCDC6 and RET fusion sequence, a standard gene containing a MET gene amplification, a standard gene containing a MYC-N gene amplification, and a standard gene containing a MYC-C gene amplification. Here, an example is shown in which the quality control sample contains 10 standard genes, but the present invention is not limited to this example.

[0174] The first and second standard genes contained in the quality control sample may be different DNA molecules or may be linked together. When the first and second standard genes are linked together, the sequence of the first and second standard genes may be directly linked together, or a spacer sequence may be interposed between the sequences of the first and second standard genes.

[0175] The spacer sequence is preferably a sequence that is unlikely to be contained in a sample to be subjected to a genetic test, for example, a sequence of multiple (e.g., 100) consecutive adenine bases.

[0176] The reference gene may be a gene included in the gene panel to be analyzed, or may not be included in the gene panel. It may be a gene of the organism to be genetically tested, or a gene of a different organism. For example, if the organism to be genetically tested is a human, the reference gene may be a gene of an animal, a plant, a bacterium, or the like other than a human.

[0177] The method for synthesizing the standard gene is not particularly limited. For example, it can be synthesized using a known DNA synthesizer. It may also be obtained by amplifying a gene derived from a template organism by PCR and purifying it. It may also be obtained by amplifying a standard gene synthesized by a DNA synthesizer as a template by PCR and purifying it.

[0178] The length of the standard gene is not particularly limited. For example, the length of the standard gene may be 50 nucleotides or more. When amplifying by PCR, a gene of up to 2000 nucleotides can be amplified easily and is preferable. When synthesizing using a DNA synthesizer, a gene of up to several kbp can be synthesized.

[0179] The concentration of the standard gene in the quality control sample is not particularly limited, and may be, for example, approximately the same as the DNA concentration in the sample.

[0180] The standard gene in the quality control sample may be single-stranded or double-stranded, and may be linear or circular.

[0181] For example, (1) a standard gene containing a substitution mutation is prepared, (2) a standard gene containing a fusion mutation is prepared, and (3) a sample for sequence analysis is prepared by mixing a quality control sample with the sample. Next, (4) the genomic DNA and the standard gene derived from the sample in the sample for sequence analysis are subjected to pretreatment (fragmentation, DNA concentration, PCR amplification using tag primers, etc.) and sequence analysis, and sequence information of the target gene is obtained. Indicators for quality control are obtained during the sequence analysis, and the quality of the analysis results of the target gene is evaluated based on the indicators of the sequence analysis of the standard DNA molecule. Based on the results of the quality evaluation, the operator can judge the reliability of the analysis results of the gene to be analyzed.

[0182] In the above example, the quality control sample and the subject-derived sample are mixed in (3), but the present invention is not limited to this. For example, the quality control sample and the subject-derived sample may not be mixed, and each may be subjected to sequence analysis in (4).

[0183] In addition, when a panel test using the same gene panel is repeatedly performed, the same quality control sample may be used repeatedly. As shown in data 121D of Fig. 20, a plurality of quality control samples each containing different standard genes and mutation types may be prepared as quality control samples corresponding to each gene panel.

[0184] By selectively using multiple quality control samples with different combinations of standard genes for each panel test, week, or month, the quality control unit 117 can generate a quality evaluation index for evaluating the quality of the process of detecting mutations in the panel test by detecting mutations in a wider variety of standard genes, thereby improving the comprehensiveness of the quality control of the panel test.

[0185] For example, Figure 21 shows quality control samples A and B, which are quality control samples corresponding to gene panel A. The standard genes a1, a2, and a3 contained in quality control sample A have been changed to standard genes b1, b2, and b3, respectively, in quality control sample B.

[0186] Next, as shown in (a) of FIG. 22, the sample (genomic DNA and / or standard gene derived from the sample) is fragmented to a length for reading the sequence with a sequencer 2 (step S301 in FIG. 15 to FIG. 18). The fragmentation of the sample DNA can be performed by a known method such as ultrasonic treatment or treatment with a reagent for fragmenting nucleic acid. The obtained DNA fragments (nucleic acid fragments) can be, for example, several tens to several hundreds of bp in length.

[0187] Next, as shown in (b) of Figure 22, adapter sequences corresponding to the type of sequencer 2 and sequencing protocol to be used are added to both ends (3' end and 5' end) of the DNA fragment obtained in step S301 (step S302 in Figures 15 to 18). Note that, although this step is essential when the sequencer 2 is an Illumina sequencer or a device that employs a similar system to the Illumina sequencer, it may be omitted when another type of sequencer 2 is used.

[0188] The adapter sequence is a sequence used to perform sequencing in a later step, and in one embodiment, can be a sequence for hybridizing to an oligo DNA immobilized on a flow cell in a bridge PCR method.

[0189] In one embodiment, as shown in the upper part of (b) of Figure 22, adapter sequences (e.g., adapter 1 sequence and adapter 2 sequence in Figure 22) may be added directly to both ends of a DNA fragment. The addition of adapter sequences to a DNA fragment can be performed using a method known in the art. For example, the DNA sequence may be blunted and the adapter sequence may be ligated.

[0190] The addition of an adaptor sequence to a DNA fragment can be performed by a method known in the art. For example, a DNA fragment may be blunted, an index sequence may be ligated, and then an adaptor sequence may be ligated.

[0191] Next, as shown in FIG. 23, a biotinylated RNA bait library is hybridized to the DNA fragment to which the adapter sequence has been added (Step S303 in FIGS. 15 to 18).

[0192] The biotinylated RNA bait library is composed of biotinylated RNA (hereinafter referred to as RNA bait) that hybridizes with the gene to be analyzed. The length of the RNA bait is arbitrary, but for example, a long oligo RNA bait of about 120 bp may be used to increase specificity.

[0193] In the panel test using the sequencer 2 in this embodiment, a large number of genes (for example, 100 or more) are the genes to be analyzed.

[0194] The reagents used in panel testing contain a set of RNA baits corresponding to each of the multiple genes. Since different panels have different numbers and types of genes to be tested, the sets of RNA baits contained in the reagents used in the panel testing are also different. When a gene other than the gene to be analyzed is used as a standard gene, it is necessary to prepare a bait that binds to the standard gene.

[0195] Then, as shown in Fig. 24, the DNA fragments to be analyzed are collected (step S304 in Figs. 15 to 18). In detail, as shown in the upper part of Fig. 24, the DNA fragments hybridized with the biotinylated RNA bait library are mixed with streptavidin magnetic beads in which streptavidin is bound to magnetic beads.

[0196] As a result, the streptavidin portion of the streptavidin magnetic beads and the biotin portion of the RNA bait are bound to each other, as shown in the middle part of Fig. 24. Then, as shown in the lower part of Fig. 24, the streptavidin magnetic beads are attracted by a magnet, and fragments that are not hybridized with the RNA bait (i.e., DNA fragments that are not to be analyzed) are removed by washing.

[0197] This allows the selection and enrichment of DNA fragments that have hybridized with the RNA bait, i.e., DNA fragments to be analyzed. The sequencer 2 obtains multiple read sequences by reading the nucleic acid sequences of the DNA fragments selected using multiple RNA baits in this way.

[0198] (Read sequence by sequencer 2) Next, the procedure of step S32 in Fig. 14 will be described along the flow shown in Fig. 25 with appropriate reference to Fig. 26 to Fig. 28. Fig. 25 is a flowchart illustrating an example of the procedure for analyzing the base sequence of a sample DNA by the sequencer 2.

[0199] As shown in the left to center columns of FIG. 26, the streptavidin magnetic beads and RNA bait are removed from the concentrated DNA fragments, and the fragments are amplified by PCR to complete the pretreatment.

[0200] First, as shown in the right column of FIG. 26, the sequence of the amplified DNA fragment is injected into a flow cell (step S305 in FIG. 25).

[0201] Next, as shown in FIG. 27, the DNA fragment to be analyzed is amplified on a flow cell by Bridge PCR (Step S306 in FIG. 25).

[0202] That is, the DNA fragment to be analyzed (e.g., Template DNA in Figure 27) has two different types of adapter sequences (e.g., Adapter 1 sequence and Adapter 2 sequence in Figure 27) added to both ends by the above-mentioned pretreatment ("1" in Figure 27), and this DNA fragment is made single-stranded and the Adapter 1 sequence on the 5' end is fixed onto the flow cell ("2" in Figure 27).

[0203] The adaptor 2 sequence on the 5' end is fixed on the flow cell in advance, and the adaptor 2 sequence on the 3' end of the DNA fragment binds to the adaptor 2 sequence on the 5' end of the flow cell, forming a bridge ("3" in Figure 27).

[0204] In this state, a DNA extension reaction is carried out using DNA polymerase ("4" in Figure 27) and then denatured to obtain two single-stranded DNA fragments ("5" in Figure 27).

[0205] By repeating this process of bridge formation, DNA extension reaction, and denaturation in this order, a large number of single-stranded DNA fragments can be locally amplified and fixed to form clusters ("6" to "10" in Figure 27).

[0206] Then, as shown in FIG. 28, the sequence is read by sequencing-by-synthesis using the single-stranded DNA forming the cluster as a template (Step S307 in FIG. 25).

[0207] First, DNA polymerase and fluorescently labeled dNTPs with blocked 3' ends are added to single-stranded DNA immobilized on a flow cell (top left column of Figure 28) (top center column of Figure 28), and then a sequence primer is added (top right column of Figure 28).

[0208] The sequence primer may be designed to hybridize to a portion of the adaptor sequence, for example. In other words, the sequence primer may be designed to amplify a DNA fragment derived from the sample DNA, and when an index sequence is added, the sequence primer may be designed to further amplify the index sequence.

[0209] After adding a sequencing primer, a one-base extension reaction of the 3'-blocked fluorescent dNTP is carried out by DNA polymerase. Because a 3'-blocked dNTP is used, the polymerase reaction stops when one base is extended. The DNA polymerase is then removed (middle right column of Figure 28), and the fluorescent substance bound to the base of the single-stranded DNA that has been extended by one base (bottom right column of Figure 28) is excited by laser light, and the light emission that occurs at this time is recorded as a photograph (bottom left column of Figure 28).

[0210] To determine the four bases, a fluorescent microscope is used to take pictures, changing the wavelength filter to capture each of the fluorescent colors corresponding to A, C, G, and T. After all the pictures are imported, the bases are determined from the photographic data. The fluorescent substance and the protecting group blocking the 3' end are then removed, and the next polymerase reaction begins. This process constitutes one cycle, and by repeating the second and third cycles, the entire length can be sequenced.

[0211] Using the above techniques, the analytical chain length can reach 150 bases x 2, making it possible to analyze in units much smaller than a picotiter plate. By increasing the density, it is possible to obtain enormous amounts of sequence information, up to 40 to 200 Gb, in a single analysis.

[0212] (Gene Panel) The gene panel used to read the lead sequence by the sequencer 2 means, as described above, an analysis kit for analyzing multiple analysis targets in a single run, and in one embodiment, may be an analysis kit for analyzing multiple gene sequences related to multiple diseases.

[0213] As used herein, the term "kit" refers to a package that includes a container (e.g., a bottle, a plate, a tube, a dish, etc.) that contains a specific material. Preferably, the package includes instructions for using each material. When used herein in the context of a kit, "included" refers to a state in which the material is contained in any of the individual containers that make up the kit. The kit may also be a package that contains multiple different compositions in one package, where the composition may be in the form described above, and may be in the form of a solution that is contained in a container.

[0214] The kit may contain substance A and substance B mixed in the same container or in separate containers. The "instructions" indicate procedures for applying each component in the kit to therapy and / or diagnosis. The "instructions" may be written or printed on paper or other media, or may be attached to electronic media such as magnetic tape, computer readable disk or tape, CD-ROM, etc. The kit may also contain containers containing diluents, solvents, washing solutions, or other reagents. Furthermore, the kit may also include tools necessary for application to therapy and / or diagnosis.

[0215] In one embodiment, the gene panel may include one or more of the above-mentioned reagents such as quality control samples, reagents for fragmenting nucleic acids, reagents for ligation, wash solutions, PCR reagents (dNTPs, DNA polymerase, etc.), and magnetic beads. The gene panel may also include one or more of oligonucleotides for adding adapter sequences to the fragmented DNA, oligonucleotides for adding index sequences to the fragmented DNA, RNA bait libraries, etc.

[0216] In particular, the index sequence of each gene panel can be a sequence specific to the gene panel for identifying the gene panel. Also, the RNA bait library of each gene panel can be a library specific to the gene panel, including RNA baits corresponding to each test gene of the gene panel.

[0217] (Sequence data reading unit 111, data adjustment unit 113, mutation identification unit 114) Next, the processing of the sequence data reading unit 111, data adjusting unit 113, and mutation identifying unit 114 of the analysis execution unit 110 will be described along the processing flow shown in FIG. 29 with appropriate reference to FIGS. 30 to 38.

[0218] 29 is a flowchart illustrating an example of the flow of analysis by the information processing device 1. The process shown in FIG. 29 corresponds to step S109 shown in FIG.

[0219] <Sequence data reading unit 111> 29, the sequence data reading unit 111 reads the read sequence information provided by the sequencer 2. The data reading unit 111 may obtain read sequence information read from an exon region of a nucleic acid sequence, or may obtain read sequence information read from an exon region of at least 10 Mb (10 million bases) or more.

[0220] The lead sequence information is data indicating the base sequence read by the sequencer 2. The sequencer 2 sequences a large number of nucleic acid fragments obtained using a specific gene panel, reads their sequence information, and provides it to the information processing device 1 as lead sequence information.

[0221] In one embodiment, the lead sequence information may include the quality score of each base in the sequence together with the read sequence. In addition, both the lead sequence information obtained by subjecting an FFPE sample collected from a lesion site of a subject to the sequencer 2 and the lead sequence information obtained by subjecting a blood sample to the sequencer 2 are input to the information processing device 1.

[0222] FIG. 30 is a diagram showing an example of a file format of read sequence information. In the example shown in FIG. 30, the read sequence information includes a sequence name, a sequence, and a quality score. The sequence name may be a sequence ID or the like assigned to the read sequence information output by the sequencer 2. The sequence indicates the base sequence read by the sequencer 2. The quality score indicates the probability that base assignment by the sequencer 2 is not performed correctly. The sequence quality score (Q) of an arbitrary base is expressed by the following formula.

[0223] Q=-10log 10 E In this formula, E represents an estimate of the probability that a base assignment will be incorrect. A higher Q value means a lower probability of error. The lower the Q value, the more of the read is unusable.

[0224] It may also lead to an increase in false positive mutation assignments, reducing the accuracy of the results. Note that a "false positive" refers to a lead sequence being determined to have a mutation when it does not have the true mutation of interest.

[0225] "Positive" means that the lead sequence has the true mutation to be determined, and "negative" means that the lead sequence does not have the mutation to be determined. For example, a quality score of 20 means that the probability of error is 1 in 100, and therefore the accuracy of each base in the read gene sequence (also called "base call accuracy") is 99%.

[0226] <Data Adjustment Unit 113> Next, in step S12 of FIG. 29, the data adjusting unit 113 performs alignment of the read sequences of each nucleic acid fragment included in the read sequence information based on the read sequence information read by the sequence data reading unit 111.

[0227] 31(a) is a diagram explaining alignment by the data adjusting unit 113. The data adjusting unit 113 performs alignment by referring to the reference sequences stored in the reference sequence database 122 and mapping the read sequence of each nucleic acid fragment to the reference sequence to be compared with the read sequence information. In one embodiment, the reference sequence database 122 stores multiple types of reference sequences corresponding to each gene to be analyzed.

[0228] In addition, the data adjustment unit 113 performs alignment on both the lead sequence information obtained by providing an FFPE sample taken from the subject's lesion site to the sequencer 2 and the lead sequence information obtained by providing a blood sample from the same subject to the sequencer 2.

[0229] Fig. 31(b) is a diagram showing an example of the format of the alignment result of the data adjusting unit 113. The format of the alignment result is not particularly limited as long as it can specify the lead sequence, the reference sequence, and the mapping position, respectively, and may include reference sequence information, lead sequence name, position information, map quality, and sequence, as shown in Fig. 31(b).

[0230] The reference sequence information is information indicating the reference sequence name (reference sequence ID) in the reference sequence database 122, the sequence length of the reference sequence, etc. The lead sequence name is information indicating the name (lead sequence ID) of each lead sequence to be aligned. The position information is information indicating the position on the reference sequence to which the leftmost base of the lead sequence is mapped (leftmost mapping position). The map quality is information indicating the mapping quality corresponding to the lead sequence. The sequence is information indicating the base sequence corresponding to each read sequence (e.g. ...GTAAGGCACGTCATA...).

[0231] Fig. 32 is a diagram showing an example of the structure of the reference sequence database 122. As shown in Fig. 32, the reference sequence database 122 stores reference sequences indicating wild-type sequences (for example, genomic sequences of chromosomes #1 to #23) and reference sequences in which known mutations are incorporated into the wild-type sequences.

[0232] Furthermore, metadata indicating information about a gene panel is attached to each reference sequence in the reference sequence database 122. The information about the gene panel attached to each reference sequence may, for example, directly or indirectly indicate the gene to be analyzed that corresponds to each reference sequence.

[0233] In one embodiment, the information selection unit 112 may control the data adjustment unit 113 to select a reference sequence corresponding to the information about the input gene panel by referring to information about the input gene panel and metadata about each reference sequence when the data adjustment unit 113 obtains a reference sequence from the reference sequence database 122.

[0234] For example, in one embodiment, the information selection unit 112 may control the data adjustment unit 113 to select a reference sequence corresponding to a gene to be analyzed that is identified by the input information on the gene panel, thereby improving the efficiency of analysis since the data adjustment unit 113 only needs to perform mapping to the reference sequence related to the used gene panel.

[0235] In another embodiment, the information selection unit 112 does not need to perform the above control. In that case, the information selection unit 112 may control the mutation identification unit 114 or the report creation unit 115, as described later.

[0236] FIG. 33 is a diagram showing an example of a known mutation incorporated into a reference sequence (not showing a wild-type sequence) included in the reference sequence database 122. The known mutation is a genetic mutation registered in an external database (e.g., COSMIC, ClinVar, etc.), and as shown in FIG. 33, the chromosomal position, gene name, and mutation are specified. In the example of FIG. 33, an amino acid mutation is specified, but a nucleic acid mutation may also be specified. The type of mutation is not particularly limited, and may be various mutations such as substitution, insertion, deletion, etc., or may be a mutation in which a part of the sequence of another chromosome or a reverse complementary sequence is bound.

[0237] Fig. 34 is a flowchart illustrating an example of detailed steps of the alignment in step S12 in Fig. 29. In one aspect, the alignment in step S12 in Fig. 29 is performed by steps S401 to S205 shown in Fig. 34.

[0238] In step S401 of Fig. 34, the data adjusting unit 113 selects the read sequences of each nucleic acid fragment included in the read sequence information acquired by the sequence data reading unit 111 that have not been aligned, and compares the selected read sequence with the reference sequence acquired from the reference sequence database 122. Then, in step S402, the data adjusting unit 113 identifies a position on the reference sequence where the degree of match with the read sequence satisfies a predetermined criterion. Here, the degree of match is a value indicating the degree to which the acquired read sequence information matches the reference sequence, and examples include the number or ratio of matching bases.

[0239] In one embodiment, the data adjusting unit 113 calculates a score indicating the degree of identity between the lead sequence and the reference sequence. The score indicating the degree of identity can be, for example, a percentage identity between the two sequences. The data adjusting unit 113, for example, determines the number of positions where the bases of the lead sequence and the bases of the reference sequence are identical, obtains the number of matching positions, and calculates the percentage by dividing the number of matching positions by the number of bases of the lead sequence compared to the reference sequence (the number of bases in the comparison window).

[0240] Figure 35(a) is a diagram showing an example of score calculation. In one embodiment, at the position shown in Figure 35(a), the score of the degree of identity between the read sequence R1 and the reference sequence is 100% because 13 bases out of 13 bases of the read sequence match, and the score of the degree of identity between the read sequence R2 and the reference sequence is 92.3% because 12 bases out of 13 bases of the read sequence match.

[0241] In addition, when calculating a score indicating the degree of identity between a lead sequence and a reference sequence, the data adjustment unit 113 may calculate a score lower than the normal calculation if the lead sequence contains a specified mutation (e.g., an insertion / deletion (InDel)) compared to the reference sequence.

[0242] In one embodiment, the data adjusting unit 113 may correct the score, for example, for a sequence in which the lead sequence includes at least one of an insertion and a deletion relative to the reference sequence, by multiplying the score calculated by the normal calculation as described above by a weighting factor according to the number of bases corresponding to the insertion / deletion. The weighting factor W may be calculated, for example, as W={1-(1 / 100)×(number of bases corresponding to the insertion / deletion)}.

[0243] Figure 35(b) is a diagram showing another example of score calculation. In one embodiment, the score of the degree of identity between the read sequence R3 and the reference sequence at the position shown in Figure 35(b) is 88% in the normal calculation because 15 bases out of 17 bases of the read sequence (* indicating deletion is also counted as one base) match, and the corrected score is 88% x 0.98 = 86%. Also, the score of the degree of identity between the read sequence R4 and the reference sequence is 81% in the normal calculation because 17 bases out of 21 bases of the read sequence match, and the corrected score is 81% x 0.96 = 77.8%.

[0244] The data adjusting unit 113 calculates the score of the degree of match while changing the mapping position of the lead sequence for each reference sequence, thereby identifying the position on the reference sequence where the degree of match with the lead sequence satisfies a predetermined criterion. In this case, an algorithm known in the art, such as dynamic programming, FASTA, or BLAST, may be used.

[0245] Returning to Figure 34, next, if there is a single position on the reference sequence whose degree of match with the lead sequence satisfies a predetermined criterion (NO in step S403), the data adjusting unit 113 aligns the lead sequence to that position, and if there are multiple positions on the reference sequence whose degree of match with the lead sequence satisfies a predetermined criterion (YES in step S403), the data adjusting unit 113 aligns the lead sequence to the position with the highest degree of match (step S404).

[0246] Then, if the data adjustment unit 113 has not aligned all of the read sequences included in the read sequence information acquired by the sequence data reading unit 111 (NO in step S405), it returns to step S401, and if it has aligned all of the read sequences included in the read sequence information (YES in step S405), it completes the processing of step S12.

[0247] <Mutation Identification Division 114> Next, returning to FIG. 29, in step S13, the mutation identification unit 114 compares the sequence of a reference sequence (alignment sequence) in which the lead sequence obtained by providing a sample collected from the lesion site of the subject is aligned with the sequence of a reference sequence in which the lead sequence obtained by providing a blood sample from the same subject is aligned.

[0248] Then, in step S14 of Fig. 29, the difference between both alignment sequences is extracted as a mutation. For example, if the alignment sequence derived from a blood sample for the same position of the same gene to be analyzed is ATCGA and the alignment sequence derived from a tumor tissue is ATCCA, the mutation identification unit 114 extracts the difference between G and C as a mutation.

[0249] In one embodiment, the mutation identification unit 114 generates a result file based on the extracted gene mutation. Figure 36 is a diagram showing an example of the format of the result file generated by the mutation identification unit 114. The format may be based on, for example, the Variant Call Format (VCF).

[0250] As shown in FIG. 36, the result file describes the position information, the reference base, and the mutated base for each extracted gene mutation. The position information indicates a position on the reference genome, and includes, for example, a chromosome number and a position on the chromosome. The reference base indicates a reference base (A, T, C, G, etc.) at the position indicated by the position information. The mutated base indicates a base after mutation of the reference base. The reference base is a base on an alignment sequence derived from a blood sample, and the mutated base is a base on an alignment sequence derived from a tumor tissue.

[0251] In FIG. 36, a mutation in which the reference base is C and the mutated base is G is an example of a substitution mutation, a mutation in which the reference base is C and the mutated base is CTAG is an example of an insertion mutation, and a mutation in which the reference base is TCG and the mutated base is T is an example of a deletion mutation. Also, a mutation in which the mutated base is G]17:198982], ]13:123456]T, C[2:321682[, or [17:198983[A] is an example of a mutation in which a partial sequence of another chromosome or a reverse complementary sequence is bound.

[0252] 29 , subsequently, in step S15, the mutation identifying unit 114 searches the mutation database 123. Then, in step S16, the mutation identifying unit 114 refers to the mutation information in the mutation database 123, and identifies the mutation by adding an annotation to the mutation included in the result file.

[0253] Fig. 37 is a diagram showing an example of the structure of the mutation database 123. The mutation database 123 is constructed based on an external database such as COSMIC or ClinVar. In one embodiment, metadata related to information on a gene panel is added to each piece of mutation information in the database. In the example shown in Fig. 37, the gene ID of the gene to be analyzed is added as metadata to each piece of mutation information in the database.

[0254] Fig. 38 is a diagram showing a detailed example of the structure of mutation information in the mutation database 123. As shown in Fig. 38, in one embodiment, the mutation information included in the mutation database 123 may include a mutation ID, position information of the mutation (e.g., "CHROM" and "POS"), "REF", "ALT", and "Annotation". The mutation ID is an identifier for identifying a mutation.

[0255] In the information on the position of the mutation, "CHROM" indicates the chromosome number, and "POS" indicates the position on the chromosome number. "REF" indicates the base in the wild type, and "ALT" indicates the base after the mutation. "Annotation" indicates information about the mutation. "Annotation" may be information indicating an amino acid mutation, such as "EGFR C2573G" or "EGFR L858R." For example, "EGFR C2573G" indicates a mutation in which the cysteine ​​at the 2573rd residue of the protein "EGFR" is replaced with glycine.

[0256] As in the above example, the "Annotation" of the mutation information may be information for converting a mutation based on base information into a mutation based on amino acid information. In this case, the mutation identification unit 114 can convert a mutation based on base information into a mutation based on amino acid information based on the referenced "Annotation" information.

[0257] The mutation identification unit 114 searches the mutation database 123 using information identifying the mutation included in the result file (e.g., position information of the mutation and base information corresponding to the mutation) as a key. For example, the mutation identification unit 114 may search the mutation database 123 using any of the information "CHROM", "POS", "REF", and "ALT" as a key. When a gene mutation extracted by comparing an alignment sequence derived from a blood sample with an alignment sequence derived from a lesion site is registered in the mutation database 123, the mutation identification unit 114 identifies the mutation as a mutation present in the sample and assigns an annotation (e.g., "EGFR L858R", "BRAF V600E", etc.) to the mutation included in the result file.

[0258] In one embodiment, the information selection unit 112 may mask (exclude) from the result file any mutations that do not correspond to the information regarding the gene panel input to the mutation identification unit 114 before the mutation identification unit 114 searches the mutation database 123 based on the result file.

[0259] For example, in one embodiment, the mutation identification unit 114 notified of information related to the gene panel from the information selection unit 112 may refer to a table showing the correspondence between the gene to be analyzed and position information (e.g., "CHROM" and "POS") as shown in (a) of Figure 39, identify the position of a mutation corresponding to the gene to be analyzed specified by the notified information on the gene panel, and mask (exclude) mutations at other positions from the result file as shown in (b) of Figure 39. This allows the mutation identification unit 114 to annotate only mutations related to the used gene panel in the result file, thereby improving the efficiency of identifying and identifying mutations.

[0260] (Drug Search Section 118) The flow of processing by the drug search section 118 to generate a list including information on drugs will be described with reference to Fig. 40. Fig. 40 is a flow chart showing an example of processing by the drug search section 118 to generate a list of drugs related to mutations.

[0261] The drug search unit 118 searches the drug database 124 using the mutation ID assigned to the genetic mutation identified by the mutation identification unit 114 as a key (step S15a). Based on the search results, the drug search unit 118 generates a list including information on drugs related to the mutation (step S16a). The generated list is incorporated into a report created by the report creation unit 115.

[0262] (Drug Database 124) When the medicine search section 118 searches the medicine database 124 to generate a medicine list, data 124A stored in the medicine database 124 will be described with reference to Fig. 41. Fig. 41 is a diagram showing an example of the data structure of the medicine database 124.

[0263] In the drug database 124, a mutation ID assigned to each mutation, a related drug name, and a drug ID assigned to each drug are stored in association with each other, as shown in Fig. 41. Note that, like the data 124A in Fig. 41 in which "Drug A" and "Drug B" are associated with the mutation ID "#3", multiple related drugs may be associated with each mutation ID.

[0264] In addition, each mutation ID in the drug database 124 may be assigned “metadata related to gene panel-related information”, which is metadata related to information related to a gene panel. The drug search unit 118 refers to this “metadata related to gene panel-related information” in response to an instruction from the information selection unit 112.

[0265] Then, the drug search unit 118 changes the range of searching the drug database 124 to the range indicated in the metadata. This allows the drug search unit 118 to narrow down the drugs to be referred to in the drug database according to the "metadata on gene panel related information" assigned to each drug and the inputted information on the gene panel, and to generate a list including information on drugs according to the information on the gene panel.

[0266] The drug search unit 118 may search the drug database 124 having the data structure shown in Fig. 42 to generate a list including other information on drugs related to the mutation. This will be described with reference to Fig. 43. Fig. 43 is a flowchart showing an example of a process in which the drug search unit 118 generates a list including information on drugs related to the mutation.

[0267] The drug search unit 118 searches the drug database 124 storing the data 124B shown in Fig. 42 to determine whether or not the related drug has been approved by an authority (FDA, PMDA, etc.). Specifically, the drug search unit 118 searches for an "approval status" indicating whether the related drug corresponding to the mutation has been approved by an authority and an "approved country" indicating which country's authority has approved the drug, using information on the mutation such as a "mutation ID" as a key (step S15b).

[0268] Based on the search results, the drug search unit 118 generates a list including the mutation, related drugs corresponding to the mutation, and information regarding the approval of the related drugs (step S16b).

[0269] The drug search unit 118 may search the drug database 124 having the data structure shown in Fig. 42 to generate a list including further information on drugs related to the mutation. This will be described with reference to Fig. 44. Fig. 44 is a flow chart showing an example of a process in which the drug search unit 118 determines the presence or absence of a drug that may be off-label use based on information obtained by searching the drug database 124, and generates a list including the determination result.

[0270] The drug search unit 118 searches the drug database 124 storing the data 124B shown in Fig. 42 to determine whether the related drug has been approved by an authority (such as the FDA or PMDA) (step S15b). If the searched drug is unapproved (NO in step S21), the drug search unit 118 associates the drug with the mutation as an unapproved drug (step S23) and creates a report on the drug related to the mutation (step S16a).

[0271] If the searched drug has been approved (YES in step S21), the drug search unit 118 determines whether the disease (disease name or disease ID) of the subject from whom the sample was collected matches the disease corresponding to the related drug searched from the drug database 124 (for example, the disease name or disease ID of the ``target disease'' shown in Figure 42) (step S22).

[0272] If the subject's disease matches the "target disease" (YES in step S22), the drug search unit 118 associates the search result drug with the mutation as an approved drug (step S24), and generates a list including the mutation, the associated drug corresponding to the mutation, and information regarding the approval of the associated drug (step S16a).

[0273] On the other hand, if the subject's disease is different from the "target disease" (NO at step S22), the drug search unit 118 determines that the searched related drug is a drug that may be off-label use, associates the determination result with the mutation (step S25), and generates a list including the mutation, the related drug corresponding to the mutation, and information regarding the approval of the related drug (step S16a).

[0274] In addition, the identification (e.g., the name of the disease, the disease ID, etc.) for identifying the disease of the subject may be input from the input unit 17 by the operator or the like when performing the genetic analysis, for example. In this case, the information selection unit 112 acquires information on the disease corresponding to the sample input by the operator to identify the disease. Alternatively, as shown in FIG. 44A, a label L1 indicating the subject ID and the sample ID, etc. may be attached to each container P1 containing the sample, and the disease ID, which is the identification information of the disease of the subject, may be acquired by reading a recording means such as a barcode L11 displayed on this label L1. Alternatively, as shown in FIG. 44B, a label L2 indicating the subject ID and the sample ID, etc. may be attached to each container P1 containing the sample, and the disease ID, which is the identification information of the disease of the subject, may be acquired by reading a recording means such as an RFID tag L21 attached to this label L2. Alternatively, the testing institution 120 may manage the sample ID, subject ID, and disease ID in association with each other, and the information selection unit 112 may acquire the disease ID corresponding to the sample based on the subject ID or the sample ID. For example, the information selection unit 112 may acquire the disease ID associated with the subject ID (or sample ID) by reading the recording means of the label attached to each container that contains the sample via a communication line. Note that the disease ID may be included in the header area of ​​the lead sequence information, and the information selection unit 112 may acquire this.

[0275] The drug database 124 may have a "CDx flag" indicating whether each drug in the database is a drug related to CDx in relation to a predetermined gene mutation and a predetermined disease, as in data 124B shown in FIG. 42. When the drug search unit 118 searches for drugs with a CDx flag of "1" ("Drug A" and "Drug B" in FIG. 42), the drug search unit 118 may generate a list including auxiliary information indicating that the detection result of a predetermined gene mutation in a predetermined disease is applicable to the CDx of the searched drug. In response to the detection of a predetermined gene mutation in a sample collected from a subject suffering from a predetermined disease (e.g., cancer, etc.), the drug search unit 118 may create a list including information that the detected gene mutation and the drug corresponding to the gene mutation are related to CDx, and auxiliary information regarding the efficacy of the drug.

[0276] In this way, the drug search unit 118 can create a list according to the disease corresponding to the sample by searching the drug database 124 in which gene mutations, target diseases, and drugs are stored in association with each other, and matching the detected gene mutation with the disease specified by the information selection unit 112. The report creation unit 115 creates a report using the list created by the drug search unit 118.

[0277] The drug search unit 118 may search the drug database 124 having the data structure shown in Fig. 45 to generate a list including information on clinical trials of drugs related to the mutation. This will be described with reference to Fig. 46. Fig. 46 is a flowchart showing an example of a process in which the drug search unit 118 generates a list including information on clinical trials of drugs.

[0278] The drug search unit 118 searches for information such as the progress of clinical trials of related drugs from the drug database 124 storing the data 124C shown in Fig. 45. Specifically, the drug search unit 118 searches for information on clinical trials of mutations, such as the "clinical trial / clinical trial status", the "country" where the clinical trial is being conducted, and the "institution" shown in Fig. 45, using the mutation ID as a key (step S15c in Fig. 46). Based on the search results, the drug search unit 118 generates a list including the mutation, the related drug corresponding to the mutation, and information on the clinical trial of the related drug (step S16c in Fig. 46).

[0279] It should be noted that data 124A shown in FIG. 41, data 124B shown in FIG. 42, and data 124C shown in FIG. 45 may be integrated into one and stored in drug database 124, or may be distributed and stored in multiple databases including drug database 124.

[0280] (Report Writing Department 115) The report creation unit 115 creates a report based on the information output by the mutation identification unit 114, the information on the gene panel provided by the information selection unit 112, and the drug list generated by the drug search unit 118 (corresponding to step S111 in FIG. 4 and FIG. 1). The information included in the created report includes the information on the gene panel, information related to the identified gene mutation, and information on the drug related to the detected gene mutation. When the testing institution 120 has signed a contract for a plan for "CDx use", the report creation unit 115 can also create a report including auxiliary information related to the efficacy of drugs applicable to CDx for subjects with a specified disease.

[0281] The report creation unit 115 may be configured to select, based on the information regarding the gene panel from the information selection unit 112, the items to be included in the report, and delete the unselected information from the report. Alternatively, the information selection unit 112 may select, as the items to be included in the report, the information related to the genes corresponding to the information regarding the gene panel input via the input unit 17, and control the report creation unit 115 so that the unselected information is deleted from the report.

[0282] (Creation of a report created for CDx use) The report creation unit 115 creates a report including auxiliary information regarding the efficacy of a predetermined drug based on at least one of the information output by the mutation identification unit 114 and the drug list generated by the drug search unit 118, and the CDx information database 124D shown in FIG. 47.

[0283] Specifically, after confirming the disease identified by the information selection unit 112, the report creation unit 115 confirms whether or not it corresponds to the gene mutation identified by the mutation identification unit 114. If the gene mutation corresponds, the report creation unit 115 may create a report that displays this gene mutation for CDx use. Alternatively, after confirming the gene mutation identified by the mutation identification unit 114, the report creation unit 115 confirms the disease identified by the information selection unit 112. If the disease corresponds, the report creation unit 115 may create a report that displays this gene mutation for CDx use.

[0284] <CDx information database 124D> The inspection institution 120 that uses the gene analysis system 100 is provided with the CDx information database 124D. FIG. 47 is a diagram showing an example of the data structure of the CDx information database. The CDx information database 124D may be stored in the drug database 124 in the same manner as the data 124A to 124C, or may be stored as an individual database.

[0285] In the CDx information database 124D, for drugs applicable to CDx, drug names, drug IDs, target diseases, gene names (or gene IDs), mutations, mutation IDs, etc. are associated with one another.

[0286] The report creation unit 115 searches for information related to CDx from the CDx information database 124D using a mutation ID or a subject's disease name or disease ID as a key, and creates a report including auxiliary information on the efficacy of CDx.

[0287] (Example of report) Next, some specific examples of reports created by report creation unit 115 will be described with reference to Figures 52 to 60. Figures 52 to 60 each show an example of a report to be created.

[0288] In the example reports shown in Figures 52 to 60, the upper left section lists a "Patient ID" indicating the subject ID, "Patient's Gender," "Patient's Disease Name," "Name of Doctor in Charge" which is the name of the doctor in charge of the subject at medical institution 210, and "Institution Name" indicating the name of the medical institution.

[0289] Below that is information about the gene panel, including the gene panel name, such as "Panel A." In addition, the report also includes quality assessment indicators, or "QC indicators," obtained from the processing and analysis results using quality control samples.

[0290] As shown in FIG. 52, the report creation unit 115 may create a report in which information related to a predetermined gene mutation associated with auxiliary information is distinguished from information related to a gene mutation different from the predetermined gene mutation. Specifically, the report creation unit 115 may create a report in which the analysis results of "CDx use" and the analysis results of "non-CDx use" are distinguished. The analysis results of "CDx use" may be displayed using a color different from that of "non-CDx use", such as displaying the analysis results of "CDx use" in red, for example, and displaying the analysis results of "non-CDx use" in black, for example. In the report created by the report creation unit 115, the heading "CDx use" is included in the auxiliary information related to the efficacy of a drug applicable to CDx.

[0291] As shown in Fig. 53, the report creation unit 115 may create a report in which information related to a predetermined gene mutation detected in a nucleic acid sequence of a sample is given a display (e.g., an icon) indicating that the gene mutation is related to auxiliary information. Specifically, the report creation unit 115 may create a report in which an icon display such as "CDx" is given to the analysis result of "CDx use". When the analysis result is electronically displayed in the input unit 17 of the information processing device 1 (for example, when displayed on a Web browser), an icon such as "CDx" may be displayed when the cursor is located at a position corresponding to the predetermined gene mutation in a list showing detected gene mutations.

[0292] As shown in Fig. 54, the report creation unit 115 may create a report including a first area including information related to a predetermined gene mutation and auxiliary information, and a second area including information related to a gene mutation different from the predetermined gene mutation. Specifically, the report creation unit 115 may create a report such that the analysis results for "CDx use" and the analysis results for "non-CDx use" are displayed in different areas (e.g., different pages) of the report. In the example shown in Fig. 52, the analysis results for "CDx use" are displayed on the third page, and the analysis results for "non-CDx use" and the like are displayed on the fourth page and thereafter.

[0293] 55, the report creation unit 115 may create a report including auxiliary information indicating that the subject from whom the sample was collected can be selected as a subject for whom a predetermined drug may be effective against a disease, based on the analysis result of the nucleic acid sequence of the sample. Specifically, the report creation unit 115 can add "*" to the analysis result of "CDx use" and display a comment such as "This analysis result is intended to assist in the selection of patients for whom drug G may be effective" as auxiliary information.

[0294] 56 to 58 show examples of reports created by report creation unit 115 in step S1115 of Fig. 48, which will be described later, and Figs. 58 to 61 show examples of reports created by report creation unit 115 in step S1115 of Fig. 49. The report shown in Fig. 60 shows an example of a report created by report creation unit 115 in step S1117 of Fig. 50.

[0295] In this way, the report creation unit 115 creates a report that clearly distinguishes between the display of gene mutations for "CDx use" and the display of gene mutations for "non-CDx use". This makes it possible to prevent the display of gene mutations for "CDx use" from being buried, since, for example, the analysis results obtained by gene panel testing display multiple gene mutations across multiple diseases. In addition, the report created in this way can provide medical institutions and the like with auxiliary information related to gene mutations applicable to CDx and efficacy of drugs in an easy-to-understand manner. This improves the usability of the report, making the use of CDx and personalized medicine based on the detection of a specific gene mutation more effective.

[0296] Note that reports such as those shown in Figs. 52 to 59 may be configured such that only information processing devices 1 installed in testing institutions that have concluded a contract for a CDx use plan are permitted to create them.

[0297] One configuration to achieve this may be such that the CDx information database 124D is provided from the management server 3 to the information processing device 1 only when a contract has been concluded for a CDx use plan (e.g., “Plan 3” and “Plan 4” shown in 3B of FIG. 5).

[0298] Alternatively, the report creation unit 115 may be configured to be permitted to create reports as shown in Figs. 52 to 59 only when the user is a user who can use CDx, such as a testing institution that has concluded a contract for a plan for CDx use. This configuration will be described with reference to Figs. 61 and 62. Fig. 61 is an example of a GUI that is displayed when a testing institution logs in to the gene analysis system. Fig. 62 is a diagram showing an example of a report that is created when the contract type of the testing institution does not include CDx use.

[0299] As shown in FIG. 61, when starting to use the gene analysis system 100, each testing institution 120 is requested to input a testing institution ID and a password. The management server 3 that receives the input testing institution ID checks the plan that the testing institution 120 has contracted with. If the plan that the testing institution 120 has contracted with includes CDx use, the report creation unit 115 of the information processing device 1 of the testing institution 120 allows the report creation as shown in FIG. 52 to FIG. 59. On the other hand, if the plan that the testing institution 120 has contracted with does not include CDx use, the report creation unit 115 of the information processing device 1 of the testing institution 120 creates a report as shown in FIG. 62, for example, and does not allow the creation of a report as shown in FIG. 52 to FIG. 59. In the example shown in FIG. 62, the report contains a message that indicates that the report is not for CDx use, saying "This report is not for CDx use."

[0300] In this configuration, confirmation of the contracted plan is not essential, and the analysis system management institution 130 may determine whether or not the user is able to use CDx based on the testing institution ID entered when starting to use the gene analysis system 100. In this case, if the testing institution ID is a user who can use CDx, the report creation unit 115 of the information processing device 1 of the testing institution 120 is permitted to create reports such as those shown in Figures 52 to 59. On the other hand, if the testing institution ID is not able to use CDx, the report creation unit 115 of the information processing device 1 of the testing institution 120 creates a report such as that shown in Figure 60, for example, and does not permit the creation of reports such as those shown in Figures 52 to 59.

[0301] That is, the report creation unit 115 can create a first report that displays genetic variations associated with the efficacy of a drug, and a second report that displays genetic variations not associated with the efficacy of the drug. (1) A report is generated according to the disease corresponding to the sample.

[0302] (2) A report is generated according to the disease corresponding to the sample and the genetic mutations identified in the nucleic acid sequence of the sample.

[0303] (3) Creating a report in which genetic mutations associated with information related to drug response (e.g., CDx applications) differ depending on the disease corresponding to the sample and the genetic mutations identified in the nucleic acid sequence of the sample.

[0304] The flow of processing in which the report creation unit 115 creates a report by referring to the CDx information database 124D shown in Fig. 47 will be described below with reference to Fig. 48. Fig. 48 is a flowchart showing an example of processing in which the report creation unit 115 creates a report including auxiliary information related to the efficacy of CDx.

[0305] If the testing institution where the information processing device 1 is installed has not signed a contract for a plan for CDx use (for example, "Plan 3" and "Plan 4" shown in 3B of FIG. 5) (NO in step S1111), the report creation unit 115 creates a report that does not include information related to drug efficacy (step S1117). Note that this plan determination is not essential, and auxiliary information related to drug efficacy applicable to CDx may be uniformly provided.

[0306] If the testing institution has concluded a contract for a plan for CDx use (YES in step S1111), proceed to step S1112. In step S1112, the report creation unit 115 checks whether or not information related to the genetic mutation (e.g., a mutation ID, etc.) notified from at least one of the mutation identification unit 114 and the drug search unit 118 exists in the CDx information database 124D shown in FIG. 47. If the genetic mutation exists in the CDx information database 124D (YES in step S1112), proceed to step S1113. On the other hand, if the predetermined genetic mutation does not exist in the CDx information database 124D (NO in step S1112), proceed to step S1115.

[0307] Next, in step S1113, the report creation unit 115 checks whether the identification information of the subject's disease acquired by the information selection unit 112 (e.g., the target disease name and the disease ID, etc.) matches the target disease corresponding to the gene mutation confirmed in the CDx information database 124D. Specifically, the report creation unit 115 uses the mutation ID of the gene mutation included in the analysis result as a key to search the CDx information database 124D and acquires the target disease corresponding to the mutation ID. If the subject's disease is included in the acquired target diseases (YES in step S1113), the report creation unit 115 proceeds to step S1114 and creates a report including information related to the efficacy of the drug. On the other hand, if the subject's disease is not included in the acquired target diseases (NO in step S1113), the report creation unit 115 proceeds to step S1115 and creates a report that can determine that the gene mutation of the CDx target was not detected.

[0308] In step S1115, the report creation unit 115 creates a report as shown in the following (1) to (3).

[0309] (1) Create a report indicating that no gene mutation of the CDx target was detected in the vicinity of the information indicating that it is for "CDx use" (for example, the display "for CDx use"). For example, as shown in FIG. 56, create a report including a message such as "No gene mutation of the CDx target was detected" indicating that no gene mutation of the CDx target was detected, or a display such as "None" or "not detected".

[0310] (2) As shown in FIG. 57, create a report that does not display the information itself indicating that it is for "CDx use".

[0311] Here, the disease identification information can be input from the input unit 17 by an operator or the like when performing gene analysis. The report creation unit 115 may be configured to obtain the input disease identification information from the information selection unit 112 and check whether it exists in the CDx information database 124D.

[0312] As described above, when a predetermined gene mutation is detected in the nucleic acid sequence of a sample associated with the identification information of a predetermined disease, the report creation unit 115 creates a report including auxiliary information regarding the efficacy of a predetermined drug. Thereby, a report including auxiliary information regarding the efficacy of a predetermined drug can be appropriately created.

[0313] <Modification Example 1 of Creation of Report Created for CDx Use> The quality control unit 117 generates a quality control index for evaluating the quality of the gene test based on the sequence information obtained by measuring the quality evaluation sample. When using the result of the gene panel test for CDx use, it is required that the reliability and accuracy of the analysis result obtained by the gene panel test meet predetermined criteria.

[0314] Therefore, as shown in FIG. 49, the report creation unit 115 may check whether at least one of the multiple quality evaluation indexes generated by the quality management unit 117 meets the predetermined standard stored in the quality evaluation standard 126 of FIG. 6 (step S1116). That is, if the quality evaluation index meets the predetermined standard (YES in step S1116), the process proceeds to S1114, and a report including information related to the efficacy of the drug is created. On the other hand, if the quality evaluation index does not meet the predetermined standard (NO in step S1116), the process proceeds to S1118, and a report that can determine that the quality evaluation index does not meet the predetermined standard is created. If the quality evaluation index does not meet the predetermined standard (NO in step S1116), a report including information indicating that the analysis result included in the created report is reference information that does not reach a normal quality level may be created. If the quality evaluation index does not meet the predetermined standard (NO in step S1116), the report creation unit 115 may be configured not to create a report.

[0315] In addition, if the quality evaluation index does not meet the specified criteria (NO in step S1116), a report may be created that can determine that no genetic mutation was detected in the CDx target, as shown in (1) or (2) below.

[0316] (1) As shown in Figure 58, gene mutations for "CDx use" and "non-CDx use" are displayed, and a comment such as "There was an item in the test QC index that did not meet the standard. This test result is for reference only" is displayed near the displayed gene mutation, indicating that the analysis results included in the created report do not reach the normal quality level and are for reference only.

[0317] (2) As shown in Figure 59, a comment such as "There were items in the QC indicators of the test that did not meet the standards" is displayed, indicating that the analysis results do not reach the normal quality level, and neither the analysis results for "CDx use" nor "non-CDx use" are displayed.

[0318] Thus, even when the quality evaluation index does not meet the predetermined standard, the report creation unit 115 creates a report that does not include auxiliary information related to the efficacy of drugs applicable to CDx, or a report that includes information indicating that the analysis results included in the report are reference information that does not reach the normal quality level. That is, in response to the quality evaluation index not meeting the predetermined standard, the report creation unit 115 may create a report that does not include information on the efficacy of drugs for a subject with a gene mutation and that can determine that no gene mutation for CDx target was detected.

[0319] <Modified Example 2 of Creation of Report Created for CDx Use> The report creation unit 115 may be configured to create different reports depending on whether a panel test is performed using a gene panel for analyzing gene mutations in genes for CDx targets. FIG. 50 is a flowchart showing an example of a process in which the report creation unit 115 creates a report including auxiliary information on the efficacy of CDx depending on whether the gene panel used is a CDx target. For the steps already described, the same step numbers are assigned and the description thereof is omitted.

[0320] Based on the data 121B shown in FIG. 9, the information selection unit 112 identifies whether the “CDx flag” of the acquired gene panel name (which may be a gene panel ID) is “1” or “0”. When the gene panel identified by the information selection unit 112 is a gene panel for CDx targets (YES in step S1111a), the report creation unit 115 proceeds to step S1112. When the gene panel identified by the information selection unit 112 is not a gene panel for CDx targets (NO in step S1111a), the report creation unit 115 proceeds to S1117 and creates a report that does not include information related to the efficacy of drugs.

[0321] According to this configuration, in a report reporting the results of a panel test using a gene panel (not a gene panel for CDx targets) that does not include a gene mutation of a CDx target as a gene to be analyzed, a report that does not include information related to drug response is created. For example, in a panel test using a gene panel that is not a gene panel for CDx targets, even if a specific gene mutation of a CDx target is detected in the nucleic acid sequence of a sample and the disease corresponding to the sample is a specific disease of a CDx target, a report that does not include information related to drug response is created, as shown in FIG.

[0322] The processing order of steps S1112 and S1113 in Figures 48 to 50 is not limited to this. For example, as shown in Figure 51, step S1112 may be performed after step S1113. Figure 51 is a flowchart showing another example of the processing in which the report creation unit 115 creates a report including auxiliary information regarding the efficacy of a predetermined drug.

[0323] In this case, the report creation unit 115 first checks in step S1113 whether the identification information of the subject's disease (e.g., the target disease name and the disease ID, etc.) acquired by the information selection unit 112 matches the target disease corresponding to the gene mutation confirmed in the CDx information database 124D. Specifically, the report creation unit 115 uses the mutation ID of the gene mutation included in the analysis result as a key to search the CDx information database 124D and acquires the target disease corresponding to the mutation ID. If the subject's disease is included in the acquired target diseases (YES in step S1113), the report creation unit 115 proceeds to step S1112. On the other hand, if the subject's disease is not included in the acquired target diseases (NO in step S1113), the report creation unit 115 proceeds to step S1112.

[0324] Next, in step S1112, the report creation unit 115 checks whether information related to the genetic mutation (e.g., mutation ID, etc.) notified from at least one of the mutation identification unit 114 and the drug search unit 118 is associated with the target disease present in step S1113. If the target disease and the genetic mutation are associated in the CDx information database 124D (YES in step S1112), the process proceeds to step S1114, where a report including information related to the efficacy of the drug is created. On the other hand, if the target disease and the genetic mutation are not associated in the CDx information database 124D (NO in step S1112), the process proceeds to step S1115, where a report capable of determining that the genetic mutation of the CDx target was not detected is created.

[0325] (Output section 13) The report created by the report creation unit 115 may be transmitted as an analysis result of the lead sequence information from the output unit 13 to the communication terminal 5 installed in the medical institution 210 (corresponding to step S112 in FIG. 4). Alternatively, the report may be transmitted to a printer (not shown) connected to the information processing device 1, and after being printed by the printer, it may be sent from the testing institution 120 to the medical institution 210 as a paper medium.

[0326] <Quality control index> Examples of quality evaluation indicators include the following:

[0327] · Index (i): Quality evaluation index indicating the quality of read sequence information by sequencer 2. Indicator (ii): A quality evaluation index that indicates the proportion of bases read by sequencer 2 among the bases contained in the multiple genes being analyzed. · Index (iii): A quality assessment index indicating the depth of read sequence information. · Index (iv): A quality assessment index that indicates the variability in the depth of read sequence information. · Index (v): A quality evaluation index indicating whether or not all mutations in each standard gene contained in the quality control sample were detected.

[0328] And, for indicator (i), Indicator (i-1): Quality score, and Indicator (i-2): Cluster concentration may be included.

[0329] Here, the above quality evaluation index will be explained with reference to FIG.

[0330] Metric (i-1): Quality score The quality score is an index that indicates the accuracy of each base in the gene sequence read by sequencer 2.

[0331] For example, when the read sequence information is output from the sequencer 2 in a FASTQ file, the quality score is also included in the read sequence information (see FIG. 30). Since the details of the quality score have already been explained, the explanation will be omitted here.

[0332] Indicator (i-2): Cluster concentration The sequencer 2 locally amplifies and fixes a large number of single-stranded DNA fragments on the flow cell to form clusters (see "9" in Figure 27). Then, a fluorescence microscope is used to image the clusters on the flow cell, and the sequence is read by detecting the fluorescent colors (i.e., different fluorescent wavelengths) corresponding to A, C, G, and T. The cluster density is an index that indicates how close the clusters of genes formed on the flow cell are to each other when sequencing.

[0333] For example, if the density of clusters becomes too high, causing them to be too close together or overlap, the contrast of the image captured from the flow cell (i.e., the signal-to-noise ratio) will be low, making it difficult to focus the fluorescence microscope, and therefore the fluorescence cannot be detected correctly, resulting in an inability to read the sequence accurately.

[0334] Indicator (ii): A quality evaluation index indicating the proportion of bases in the target region read by sequencer 2 out of the bases read by sequencer 2 This index indicates how many bases in the target region have been read out of the bases read by sequencer 2 (including bases outside the target region), and can be calculated as the ratio of the total number of bases read to the total number of bases in the target region.

[0335] Metric (iii) is a quality evaluation index that indicates the depth of read sequence information.

[0336] This index is based on the total number of read sequence information pieces for each base contained in the gene being analyzed, and can be calculated as the ratio of the total number of bases read whose depth is equal to or greater than a predetermined value to the total number of bases read.

[0337] The depth means the total number of read sequence information read for the same base.

[0338] FIG. 63 shows a graph indicating the depth of each base read when the entire length of the gene to be analyzed is T bases and the bases in the read region are t1 bases. The horizontal axis of this graph indicates the position of the base, and the vertical axis indicates the depth of each base. In the example shown in FIG. 63, the total number of bases in the region having a depth of a predetermined value (e.g., 100) or more among the t1 bases in the read region is (t2+t3) bases. In this case, the index (iii) is generated as the value of (t2+t3) / t1.

[0339] Indicator (iv): A quality assessment index that indicates the variability in the depth of read sequence information.

[0340] This index is an index showing the uniformity of depth. When there is an extremely large amount of read sequence information only from a certain part of the read region, the uniformity of depth is low, and when the read sequence information is present relatively evenly throughout the read region, the uniformity of depth is high. The uniformity of depth can be quantified, for example, using the interquartile range (IQR), although this is not limited thereto. A higher IQR indicates lower uniformity, and a lower IQR indicates higher uniformity.

[0341] Index (v): A quality evaluation index indicating whether all mutations in each standard gene contained in the quality control sample were detected.

[0342] This index indicates that the mutations in each standard gene contained in the quality control sample have been detected and correctly identified. For example, the mutations in each standard gene contained in quality control sample A shown in (a) of FIG. 21 and quality control sample B shown in (b) of FIG. 21 (see the "Variant" column) are known mutations. An index for evaluating whether the positions and types of these mutations have been correctly identified is used as a quality evaluation index.

[0343] The present invention is not limited to the above-described embodiments, and various modifications are possible within the scope of the claims. Embodiments obtained by appropriately combining the technical means disclosed in different embodiments are also included in the technical scope of the present invention.

[0344] The information processing device 1 is a computer that executes instructions of a program, which is software that realizes each function. This computer includes, for example, one or more processors, and a computer-readable recording medium that stores the program. In the computer, the processor reads the program from the recording medium and executes it, thereby achieving the object of the present invention. The processor can be, for example, a CPU (Central Processing Unit). The recording medium can be a "non-transient tangible medium," such as a ROM (Read Only Memory), a tape, a disk, a card, a semiconductor memory, a programmable logic circuit, or the like. The computer may further include a RAM (Random Access Memory) that expands the program. The program may be supplied to the computer via any transmission medium (such as a communication network or a broadcast wave) that can transmit the program. One aspect of the present invention can also be realized in the form of a data signal embedded in a carrier wave, in which the program is embodied by electronic transmission.

[0345] [Other Aspect 1] The present invention also includes the following aspects.

[0346] An analysis method according to one embodiment of the present invention is an analysis method for analyzing the nucleic acid sequence of a sample using a computer (information processing device 1). The computer is provided with a database (124) in which information on gene mutations, drug information, information on the target disease of the drug, and information on multiple organizations or countries that have approved the drug are stored in association with each other, and the computer identifies a specific mutation based on sequence information read from the nucleic acid sequence by a sequencer (2) (steps S1, S1112), identifies the disease corresponding to the sample, searches the database (124) for a drug that is associated with the identified specific mutation and the identified disease and that has been approved by at least one of the multiple organizations or countries, and creates a report including information related to the effectiveness of the searched drug based on the search results (steps S3, S1114).

[0347] According to the above configuration, a predetermined mutation is identified in the nucleic acid sequence of a sample, and a report including information related to the efficacy of a predetermined drug corresponding to the predetermined mutation is created according to the disease corresponding to the sample. This makes it possible to create a report including information related to the efficacy of a drug applicable to companion diagnostics (CDx) based on the results of a panel test using a gene panel that can simultaneously analyze multiple abnormalities in multiple genes related to multiple diseases. The report created in this way makes it easy to determine the predetermined mutation applicable to CDx in the results of the gene panel test. If such a report is provided to a medical institution, the use of drugs related to the efficacy of drugs applicable to CDx based on the detection of the predetermined mutation and personalized medicine can be made more effective.

[0348] In the above-mentioned analysis method, a disease corresponding to the sample may be identified, and a report including information related to the efficacy of a predetermined drug may be generated in response to the identification of the predetermined disease.

[0349] The above-mentioned analysis method may be configured to identify a disease corresponding to the sample, and generate a report including information related to the efficacy of a specified drug in response to detection of a specified mutation in the specified disease.

[0350] In the above analysis method, the presence or absence of a predetermined mutation associated with the efficacy of the searched drug and other mutations not associated with the efficacy of the searched drug may be determined based on the sequence information.

[0351] For example, when a specific mutation is detected in a sample taken from a subject suffering from cancer or the like, this analysis method can be used to create a report that displays information related to the efficacy of a drug that can be applied to the CDx corresponding to the specific mutation.

[0352] In the above analysis method, a report may be generated in which a predetermined mutation associated with the efficacy of the searched drug is distinguished from other mutations not associated with the efficacy of the searched drug.

[0353] In the above analysis method, a report may be generated in which the predetermined mutation is associated with information regarding the efficacy of the searched drug.

[0354] In the above analysis method, a report may be created that includes a first area displaying specific mutations related to the efficacy of the searched drug, and a second area displaying other mutations not related to the efficacy of the searched drug.

[0355] In the above analysis method, a report displaying a specific mutation associated with the searched drug's efficacy and a report displaying other mutations not associated with the searched drug's efficacy may be generated.

[0356] In the above analysis method, a report may be generated in which an icon indicating that the mutation is related to the efficacy of a specific searched drug is associated with the specific mutation.

[0357] In the above analysis method, a report may be created which includes information indicating that a specific mutation has been detected in the nucleic acid sequence of the sample, and which displays information indicating that the subject from whom the sample was taken can be selected as a subject for whom the searched-for drug may be effective.

[0358] In the above analysis method, a report may be generated that displays information regarding the efficacy of the searched drugs depending on whether a quality assessment index relating to the quality of the analysis of the nucleic acid sequence satisfies a predetermined standard.

[0359] In the above-mentioned analysis method, the quality evaluation index may indicate the accuracy of reading each base in the sequence information read by the sequencer (2).

[0360] In the above analysis method, the quality assessment index may indicate the depth of the sequence information read.

[0361] In the above-mentioned analysis method, the quality evaluation index may indicate a variation in depth of the read sequence information.

[0362] In the above-mentioned analysis method, the sequence information may be information read from a cluster group of nucleic acid sequences amplified on a flow cell, and the quality evaluation index may indicate the degree of proximity of clusters in the cluster group.

[0363] In the above analysis method, if the quality assessment index does not satisfy a predetermined standard, a report may be generated that includes information indicating that the analysis result of the nucleic acid sequence is reference information.

[0364] In the above analysis method, in response to the quality assessment index not meeting a predetermined criterion, a report may be generated that does not include information regarding the efficacy of the retrieved drugs.

[0365] In the above analysis method, if the quality assessment index does not satisfy a predetermined standard, a report may be generated which includes information indicating that a specified mutation was detected in the nucleic acid sequence of the sample, and which includes information indicating that the subject from whom the sample was collected cannot be selected as a subject for whom the searched drug may be effective.

[0366] In the above-mentioned analysis method, the predetermined mutation may be a nucleotide substitution, deletion, or insertion, a polymorphism, a gene copy number abnormality, or a gene fusion.

[0367] In the above-mentioned analysis method, the sequence information may be sequence information read from an exon region of a nucleic acid sequence.

[0368] In the above-mentioned analysis method, the sequence information may be sequence information read from an exon region of 10 million bases or more.

[0369] In the above-mentioned analysis method, the sequence information may be obtained via a communication line.

[0370] In the above-mentioned analysis method, information corresponding to the sample may be obtained based on an input by an operator of the computer (information processing device 1).

[0371] In the above-mentioned analysis method, information on a disease corresponding to the sample may be obtained based on identification information attached to the sample.

[0372] In the above-mentioned analysis method, information on the disease corresponding to the sample may be acquired via a communication line.

[0373] In the above-mentioned analysis method, information on the efficacy of a drug for a predetermined mutation may be obtained via a communication line.

[0374] An analytical method according to another embodiment of the present invention is an analytical method for analyzing the nucleic acid sequence of a sample using a computer (information processing device 1), identifying a specific mutation based on sequence information read from the nucleic acid sequence, discriminating a disease corresponding to the sample, and generating a report including information regarding the efficacy of a specific drug in response to detection of the specific mutation in a sample for the specific disease.

[0375] According to the above configuration, in response to detection of a predetermined mutation in a sample for a predetermined disease, a report including information on the efficacy of a predetermined drug is generated, thereby making it possible to appropriately generate a report displaying information on the efficacy of the drug.

[0376] In the above-mentioned analysis method, the presence or absence of a predetermined mutation may be determined by a computer (information processing device 1), and a report may be created by the computer (information processing device 1).

[0377] An information processing device (1) according to another aspect of the present invention is an information processing device (1) for analyzing the nucleic acid sequence of a sample, and includes a memory unit (12) for storing a database (124) in which information on gene mutations, information on drugs, information on the target disease of the drug, and information on a plurality of organizations or countries that have approved the drug are stored in association with each other; a sequence data reading unit (111) for acquiring sequence information read from the nucleic acid sequence by a sequencer (2); a mutation identification unit (114) for identifying a specific mutation in the nucleic acid sequence based on the sequence information; an information selection unit (112) for identifying a disease corresponding to the sample; a drug search unit (118) for searching the database (124) for drugs that are associated with the identified specific mutation and the identified disease and that have been approved by at least one of the multiple organizations or countries; and a report creation unit (115) for creating a report including information related to the efficacy of the searched drug based on the search results.

[0378] According to the above configuration, the information processing device (1) identifies a predetermined mutation in sequence information read from a nucleic acid sequence, and creates a report displaying information related to the efficacy of a predetermined drug corresponding to the predetermined mutation according to a disease corresponding to a sample. This makes it possible to appropriately create a report including information related to the efficacy of a drug corresponding to a predetermined mutation, even in a gene panel test that can simultaneously analyze multiple abnormalities in multiple genes related to multiple diseases.

[0379] The report creation unit (115) may create a report including information related to the efficacy of a given drug in response to the identification of a given disease.

[0380] The report creation unit (115) may create a report including information related to the efficacy of a given drug in response to detection of a given mutation in a given disease.

[0381] The drug search unit (118) may determine, based on the sequence information, a predetermined mutation associated with the efficacy of the searched drug and other mutations not associated with the efficacy of the searched drug.

[0382] The report creation unit (115) may create a report in which a predetermined mutation associated with the efficacy of the searched drug is distinguished from other mutations not associated with the efficacy of the searched drug.

[0383] The report creation unit (115) may create a report in which the predetermined mutation is associated with information regarding the efficacy of the searched drug.

[0384] The report creation unit (115) may create a report including a first area displaying specific mutations related to the efficacy of the searched drug, and a second area displaying other mutations not related to the efficacy of the searched drug.

[0385] The report creation unit (115) may create a report displaying certain mutations associated with the efficacy of the searched drug and a report displaying other mutations not associated with the efficacy of the searched drug.

[0386] The report creation unit (115) may create a report in which an icon indicating that the mutation is related to the efficacy of the searched drug is associated with the predetermined mutation.

[0387] The report creation unit (115) may create a report that includes information indicating that a specific mutation was detected in the nucleic acid sequence of the sample, and displays information indicating that the subject from whom the sample was collected can be selected as a subject for whom the searched drug may be effective.

[0388] The report creation unit (115) may create a report displaying information regarding the efficacy of the searched drug in response to the quality assessment index relating to the quality of the analysis of the nucleic acid sequence satisfying a predetermined standard.

[0389] The quality evaluation index may indicate the accuracy of reading each base in the sequence information read by the sequencer (2).

[0390] The quality assessment metric may indicate the depth of the sequence information read.

[0391] The quality assessment index may indicate the variability in the depth of the sequence information read.

[0392] The sequence data reading unit (111) acquires sequence information read from a cluster group of nucleic acid sequences amplified on a flow cell, and the quality assessment index may indicate the degree of proximity of clusters in the cluster group.

[0393] If the quality assessment index does not satisfy a predetermined standard, the report creation unit (115) may create a report including information indicating that the analysis result of the nucleic acid sequence is reference information.

[0394] The depth of the read sequence information, the variability of the depth of the read sequence information, and the proximity between clusters can all be quality evaluation indices for appropriately evaluating the quality of the analysis results of the nucleic acid sequence analysis. By applying these quality evaluation indices, a report based on the analysis results of the nucleic acid sequence analysis with sufficient accuracy can be generated.

[0395] The report creation unit (115) may create a report that does not include information regarding the efficacy of the retrieved medicine in response to the quality assessment index not satisfying the predetermined criteria.

[0396] The report creation unit (115) may create a report including information indicating that a specified mutation identified in the nucleic acid sequence of the sample was detected in response to the quality assessment index not satisfying a specified standard, and including information indicating that the subject from whom the sample was collected cannot be selected as a subject for whom the searched drug may be effective.

[0397] The mutation identification unit (114) may identify nucleotide substitutions, deletions, or insertions, polymorphisms, gene copy number abnormalities, or gene fusions in a nucleic acid sequence based on the sequence information.

[0398] The sequence data reading unit (111) may obtain sequence information read from an exon region of a nucleic acid sequence.

[0399] The sequence data reading unit (111) may obtain sequence information read from an exon region of 10 million bases or more.

[0400] The sequence data reading unit (111) may obtain the sequence information via a communication line.

[0401] The information selection unit (112) may acquire information on the disease corresponding to the sample input by the operator.

[0402] The information selection section (112) may acquire information on the disease corresponding to the sample based on identification information for identifying the sample.

[0403] For example, the information selection unit (112) may be configured to obtain the sample ID and information related to the disease corresponding to the sample by reading a recording means such as a barcode or RFID attached to a container that contains the sample.

[0404] The information selection section (112) may acquire information on the disease corresponding to the sample via a communication line.

[0405] The information processing device (1) may obtain information regarding the efficacy of a drug against a predetermined mutation via a communication line.

[0406] A program according to another aspect of the present invention is a program for causing a computer having a database (124) in which information on gene mutations, information on drugs, information on diseases targeted by the drugs, and information on a plurality of organizations or countries that have approved the drugs, are stored in association with each other, to execute the following steps: identifying a specific mutation based on sequence information read from the nucleic acid sequence of a sample by a sequencer (2) (steps S1, S1112); identifying a disease corresponding to the sample (steps S2, S1113); searching the database (124) for a drug that is associated with the identified specific mutation and the identified disease and that has been approved by at least one of the organizations or countries (step S15b); and creating a report including information related to the efficacy of the searched drug based on the search results (steps S3, S1114).

[0407] According to the above configuration, the same effects as those of the analysis method according to one aspect of the present invention are achieved.

[0408] [Other aspect 2] The present invention also includes the following aspects.

[0409] A method according to one embodiment of the present invention is a method for creating reports corresponding to multiple types of gene panels using a computer (information processing device 1), in which the computer (information processing device 1) acquires identification information of the gene panel used in the test, test results including information indicating gene mutations detected in the test, and disease information corresponding to the sample subjected to the test, and identifies a mutation for a companion diagnostic target corresponding to the identification information based on the test results and the disease information, and creates a report including information related to the efficacy of a drug corresponding to the mutation for the companion diagnostic target.

[0410] The report may display information relating to the mutations targeted by the companion diagnostics and the efficacy of the drug in association with each other.

[0411] In the report, information indicating that the mutation is a target for companion diagnostics may be displayed in association with information related to the efficacy of the drug.

[0412] In the report, information indicating that the mutation is the subject of companion diagnostics may be displayed as an icon.

[0413] In the report, a mutation that is the subject of companion diagnosis may be displayed in a distinguishable manner from other mutations that are different from the mutation that is the subject of companion diagnosis.

[0414] The report may include a first area displaying information related to the mutation(s) of the companion diagnostic target and drug response, and a second area displaying information related to other mutations.

[0415] A first report may be generated that displays information related to the mutations of interest for companion diagnostics and drug response, and a second report that displays information related to other mutations.

[0416] The report may display the presence or absence of a mutation that is the subject of the companion diagnosis in an identifiable manner.

[0417] At least one of the multiple types of gene panels can be used to test for multiple types of diseases, and at least one of the multiple gene mutations detected in the test may be identified as being a mutation to be subjected to companion diagnostics depending on whether it is detected in a sample corresponding to at least one of the multiple types of diseases.

[0418] The computer (information processing device 1) may include a database in which identification information and information on the subject of companion diagnosis are recorded in association with each other for each of a plurality of types of gene panels.

[0419] The information regarding the companion diagnosis subject may include at least one of information regarding whether the gene panel is a companion diagnosis subject, mutation information regarding the companion diagnosis subject, drug information regarding the companion diagnosis subject, and disease information regarding the companion diagnosis subject.

[0420] The report may include information regarding clinical trials of drugs related to the genetic mutations detected by the test.

[0421] The report may include the name of the gene panel used in the test.

[0422] The report may include the name of the disease corresponding to the sample.

[0423] An information processing device according to one embodiment of the present invention is an information processing device (1) that outputs reports corresponding to multiple types of gene panels, and includes: a control unit (11) that acquires identification information of the gene panel used in the test, test results including information indicating gene mutations detected in the test, and disease information corresponding to the sample subjected to the test, and performs analysis; a memory unit (12) that stores various data used in the analysis; and an output unit (13) that outputs a report corresponding to the gene panel, which is created by analysis based on the identification information, the test results, and the disease information. The control unit (11) identifies a companion diagnostic target mutation corresponding to the identification information based on the test results and the disease information, and creates a report including information related to the efficacy of a drug corresponding to the companion diagnostic target mutation.

[0424] A program according to one embodiment of the present invention is a program that causes a computer (information processing device 1) to create a report corresponding to each of multiple types of gene panels, and causes the computer (information processing device 1) to execute the steps of acquiring identification information of the gene panel used in the test, test results including information indicating gene mutations detected in the test, and disease information corresponding to the sample subjected to the test, identifying a companion diagnosis target mutation corresponding to the identification information based on the test results and the disease information (S1112 in Figures 49 to 51), and creating a report including information related to the efficacy of a drug corresponding to the companion diagnosis target mutation (S1114 in Figures 49 to 51).

[0425] [Other Aspect 3] The present invention also includes the following aspects.

[0426] In order to solve the above problems, an analytical method according to one embodiment of the present invention is an analytical method for analyzing the nucleic acid sequence of a sample by a computer, in which the computer analyzes genetic mutations in the nucleic acid sequence based on sequence information obtained by reading the nucleic acid sequence by a sequencer, searches for at least one drug related to the genetic mutation, and if at least one drug that is approved in at least one of a plurality of countries as being effective against a disease corresponding to the sample is found, creates a report including information on the genetic mutation, the drug, and the country in which the drug is approved.

[0427] In the analysis method, when at least one drug that has been approved in at least one of a plurality of countries as being effective against the disease is found, the computer may create the report further including information indicating that the drug and the gene mutation are companion diagnostic results.

[0428] In the analysis method, the computer may generate the report including information indicating that the genetic mutation for companion diagnostics was not detected if the drug approved in at least one of a plurality of countries as having an efficacy for the disease is not found.

[0429] In the analysis method, the computer may create the report further including information indicating that, among the found drugs, a drug that has not been approved in any of a plurality of countries as being effective for the disease is effective for a disease different from the disease corresponding to the sample.

[0430] In the analysis method, the information regarding a country in which the drug is approved may include the name of the country.

[0431] An information processing device according to one embodiment of the present invention is an information processing device that analyzes the nucleic acid sequence of a sample, and includes: a mutation identification unit that analyzes genetic mutations in the nucleic acid sequence based on sequence information obtained by reading the nucleic acid sequence with a sequencer; a drug search unit that searches for at least one drug related to the genetic mutation; and a report creation unit that, when at least one drug that is approved in at least one of a plurality of countries as being effective against a disease corresponding to the sample is searched for, creates a report including information on the genetic mutation, the drug, and the country in which the drug is approved.

[0432] In the information processing device, the report creation unit may create the report further including information indicating that the drug and the gene mutation are companion diagnostic results when at least one of the searched drugs has been approved in at least one of a plurality of countries as being effective for the disease.

[0433] In the information processing device, the report creation unit may create the report including information indicating that the genetic mutation related to companion diagnosis was not detected if the drug approved in at least one of a plurality of countries as being effective for the disease is not found.

[0434] In the information processing device, the report creation unit may create the report further including information indicating that, among the searched drugs, a drug that has not been approved in any of a plurality of countries as being effective for the disease is recognized to be effective for a disease different from the disease corresponding to the sample.

[0435] In the information processing device, the information regarding a country in which the drug is approved may include the name of the country.

[0436] A report providing method according to one embodiment of the present invention is a report providing method in which a report including analysis results of a nucleic acid sequence of a sample is provided by a genetic analysis system, wherein the genetic analysis system receives a request for analysis of the nucleic acid sequence of the sample derived from a patient suffering from a disease, and provides the report including the analysis results of the nucleic acid sequence read by a sequencer to the source of the analysis request, and when at least one drug that has been searched for as being effective against the disease based on a genetic mutation in the nucleic acid sequence, the report includes information on the genetic mutation, the drug, and the country in which the drug is approved.

[0437] In the report providing method, the report may further include information indicating that, if at least one of the searched drugs is approved in at least one of a plurality of countries as being effective for the disease, the drug and the genetic mutation are related to a companion diagnosis.

[0438] In the report providing method, the report may include information indicating that the genetic mutation for companion diagnostics was not detected if the drug approved in at least one of a plurality of countries as having an efficacy for the disease is not found.

[0439] In the report providing method, the report may further include information indicating that, among the found drugs, a drug that has not been approved in any of a plurality of countries as being effective for the disease is effective for a disease other than the disease corresponding to the sample.

[0440] In the method for providing a report, the information regarding a country in which the drug is approved may include a name of the country. [Explanation of symbols]

[0441] 1. Information processing device 2. Sequencer 3 Management Server 4. Communication lines 11 Control section 111 Sequence data reading unit 112 Information Selection Section 114 Mutation Identification Division 115 Report Writing Department 118 Drug Search Department

Claims

1. 1. A method for computer-based analysis of a nucleic acid sequence of a sample, comprising: The computer includes: analyzing gene mutations in the nucleic acid sequence based on sequence information obtained by reading the nucleic acid sequence with a sequencer; Based on at least one of the genetic mutations found by the analysis, a first drug associated with the genetic mutation for which a companion diagnosis is applicable for a predetermined disease and a second drug associated with the genetic mutation for which a companion diagnosis is not applicable for the predetermined disease are searched for; Based on the results of the search, a report is generated in which a first analysis result including information on the first drug and information on the genetic mutation associated with the first drug and a second analysis result including information on the second drug and information on the genetic mutation associated with the second drug are displayed in a distinguishable manner. Analysis method.

2. The computer includes: Generate the report in which the first analysis result and the second analysis result are displayed in different areas. The analysis method according to claim 1 .

3. The computer includes: generating the report that displays information regarding the first analysis result that indicates that the analysis result is related to a companion diagnostic; The analysis method according to claim 1 .

4. The computer includes: If the first agent is not found, generating the report including information indicating that the genetic mutation associated with the companion diagnostic was not detected. The analysis method according to claim 1 .

5. The computer includes: generating the report including information about the second drug that is found to be effective against a disease different from the predetermined disease; The analysis method according to claim 1 .

6. The computer includes: The report is generated on a page where the first analysis result is displayed and a page where the second analysis result is displayed. The analysis method according to claim 1 .

7. An information processing device for analyzing a nucleic acid sequence of a sample, comprising: a mutation identification unit that analyzes a genetic mutation in the nucleic acid sequence based on sequence information obtained by reading the nucleic acid sequence with a sequencer; A drug search unit that searches for a first drug associated with the genetic mutation for which companion diagnosis is applicable for a predetermined disease and a second drug associated with the genetic mutation for which companion diagnosis is not applicable for the predetermined disease, based on at least one of the genetic mutations discovered by analysis; a report generating unit that generates a report in which a first analysis result including information on the first drug and information on the genetic mutation associated with the first drug and a second analysis result including information on the second drug and information on the genetic mutation associated with the second drug are displayed in a distinguishable manner based on a result of the search; An information processing device comprising:

8. The report generation unit Generate the report in which the first analysis result and the second analysis result are displayed in different areas. The information processing device according to claim 7.

9. The report generation unit generating the report that displays information regarding the first analysis result that indicates that the analysis result is related to a companion diagnostic; The information processing device according to claim 7.

10. The report generation unit If the first agent is not found, generating the report including information indicating that the genetic mutation associated with the companion diagnostic was not detected. The information processing device according to claim 7.

11. The report generation unit generating the report including information about the second drug that is found to be effective against a disease different from the predetermined disease; The information processing device according to claim 7.

12. The report generation unit The report is generated on a page where the first analysis result is displayed and a page where the second analysis result is displayed. The information processing device according to claim 7.

13. A method for providing a report including an analysis result of a nucleic acid sequence of a sample by an information processing system, comprising: The information processing system includes: receiving a request for analysis of a nucleic acid sequence of the sample derived from a patient suffering from a disease; providing the report including the analysis result of the nucleic acid sequence read by the sequencer to an analysis requester; The report states: A first analysis result including information on the first drug and the genetic mutation associated with the first drug and a second analysis result including information on the second drug and the genetic mutation associated with the second drug are displayed in a distinguishable manner in response to a search result for a first drug associated with a genetic mutation for which a companion diagnosis is applied for a predetermined disease and a second drug associated with which a companion diagnosis is not applied for the predetermined disease based on at least one genetic mutation found by analysis. A method for providing a report.

14. The report states: The first analysis result and the second analysis result are displayed in different areas. The method of claim 13.

15. The report states: Regarding the first analysis result, information indicating that the analysis result is related to a companion diagnosis is included. The method of claim 13.

16. The report states: If the first drug was not detected, the genetic mutation associated with the companion diagnostic was not detected. The method of claim 13.

17. The report states: The second drug is effective against a disease different from the predetermined disease. The method of claim 13.

18. The report states: Displaying the first analysis result and the second analysis result on different pages The method of claim 13.

Citation Information

Patent Citations

  • System and method for determining individualized medical intervention for disease state

    JP2015200678A

  • Recording medium storing gene information / medical care information, and management system and method of gene information / medical care information using the recording medium

    JP2016014984A

  • Systems and methods for optimizing drug therapies

    US20150154375A1

  • Genome analysis device and genome visualization method

    WO2016175330A1

  • Informatics platform for integrated clinical care

    WO2017042396A1